

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TOPAMAX® safely and effectively. See full prescribing information for TOPAMAX®.

TOPAMAX® (topiramate) TABLETS

TOPAMAX® (topiramate capsules) SPRINKLE CAPSULES

Initial U.S. Approval – 1996

-----**RECENT MAJOR CHANGES**-----

- Warnings and Precautions (5.3) [04/2009]
- Warnings and Precautions (5.8) [12/2009]

-----**INDICATIONS AND USAGE**-----

TOPAMAX® is an antiepileptic (AED) agent indicated for:

- Monotherapy epilepsy: Initial monotherapy in patients ≥10 years of age with partial onset or primary generalized tonic-clonic seizures (1.1).
- Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients ≥2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) (1.2).
- Migraine: Treatment for adults for prophylaxis of migraine headache (1.3).

-----**DOSAGE AND ADMINISTRATION**-----

See DOSAGE AND ADMINISTRATION, Epilepsy: Adjunctive Therapy Use for additional details (2.1).

| | Initial Dose | Titration | Recommended Dose |
|--|--------------------------------|--|-------------------------------------|
| Epilepsy monotherapy: adults and pediatric patients ≥10 years (2.1) | 50 mg/day in two divided doses | The dosage should be increased weekly by increments of 50 mg for the first 4 weeks then 100 mg for weeks 5 to 6. | 400 mg/day in two divided doses |
| Epilepsy adjunctive therapy: adults with partial onset seizures or LGS (2.1) | 25 to 50 mg/day | The dosage should be increased weekly to an effective dose by increments of 25 to 50 mg. | 200-400 mg/day in two divided doses |
| Epilepsy adjunctive therapy: adults with primary generalized tonic-clonic seizures (2.1) | 25 to 50 mg/day | The dosage should be increased weekly to an effective dose by increments of 25 to 50 mg. | 400 mg/day in two divided doses |

| | Initial Dose | Titration | Recommended Dose |
|---|--|---|--|
| Epilepsy adjunctive therapy: pediatric patients with partial onset seizures, primary generalized tonic-clonic seizures or LGS (2.1) | 25 mg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week | The dosage should be increased at 1- or 2- week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses). Dose titration should be guided by clinical outcome. | 5 to 9 mg/kg/day in two divided doses |
| Migraine (2.3) | 25 mg/day administered nightly for the first week | The dosage should be increased weekly by increments of 25 mg. Dose and titration should be guided by clinical outcome. | 100 mg/day administered in two divided doses |

-----**DOSAGE FORMS AND STRENGTHS**-----

- Tablets: 25 mg, 50 mg, 100 mg, and 200 mg (3)
- Sprinkle Capsules: 15 mg and 25 mg (3)

-----**CONTRAINDICATIONS**-----

None.

-----**WARNINGS AND PRECAUTIONS**-----

- Acute myopia and secondary angle closure glaucoma: Untreated elevated intraocular pressure can lead to permanent visual loss. The primary treatment to reverse symptoms is discontinuation of TOPAMAX® as rapidly as possible (5.1).
- Oligohidrosis and hyperthermia: Monitor decreased sweating and increased body temperature, especially in pediatric patients (5.2).
- Suicidal behavior and ideation: Antiepileptic drugs increase the risk of suicidal behavior or ideation (5.3).
- Metabolic acidosis: Baseline and periodic measurement of serum bicarbonate is recommended. Consider dose reduction or discontinuation of TOPAMAX® if clinically appropriate (5.4).
- Cognitive/neuropsychiatric: TOPAMAX® may cause cognitive dysfunction. Patients should use caution when operating machinery including automobiles. Depression and mood problems may occur in epilepsy and migraine populations (5.5).
- Withdrawal of AEDs: Withdrawal of TOPAMAX® should be done gradually (5.6).
- Hyperammonemia and encephalopathy associated with or without concomitant valproic acid use: Patients with inborn errors of metabolism or reduced mitochondrial activity may have an increased risk of hyper-ammonemia. Measure ammonia if encephalopathic symptoms occur (5.8).

- Kidney stones: Use with other carbonic anhydrase inhibitors, other drugs causing metabolic acidosis, or in patients on a ketogenic diet should be avoided (5.9).

-----**ADVERSE REACTIONS**-----

The most common (>5% more frequent than placebo or low dose topiramate in monotherapy) adverse reactions in controlled, epilepsy clinical trials were paresthesia, anorexia, weight decrease, fatigue, dizziness, somnolence, nervousness, psychomotor slowing, difficulty with memory, difficulty with concentration/attention, and confusion. The most common (>5% more frequent than placebo) adverse reactions in controlled, migraine clinical trials were paresthesia and taste perversion.

TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT ORTHO-MCNEIL NEUROLOGICS AT 1-800-526-7736 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.

-----**DRUG INTERACTIONS**-----

Summary of antiepileptic drug (AED) interactions with TOPAMAX® (7.1).

| AED Co-administered | AED Concentration | TOPAMAX Concentration |
|--------------------------|----------------------------------|-----------------------|
| Phenytoin | NC or 25% increase ^a | 48% decrease |
| Carbamazepine (CBZ) | NC | 40% decrease |
| CBZ epoxide ^b | NC | NE |
| Valproic acid | 11% decrease | 14% decrease |
| Phenobarbital | NC | NE |
| Primidone | NC | NE |
| Lamotrigine | NC at TPM doses up to 400 mg/day | 13% decrease |

^a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin.

^b = Is not administered but is an active metabolite of carbamazepine.

NC = Less than 10% change in plasma concentration.

NE = Not Evaluated

- Concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy (5.7).
- Oral contraceptives: Decreased contraceptive efficacy and increased breakthrough bleeding should be considered, especially at doses greater than 200 mg/day (7.3).
- Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4)
- Lithium levels should be monitored when co-administered with high-dose topiramate (7.5)
- Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6)

-----**USE IN SPECIFIC POPULATIONS**-----

- Renal Impairment: In renally impaired patients (creatinine clearance less than 70 mL/min/1.73 m²), one half of the adult dose is recommended (2.4).

- Patients Undergoing Hemodialysis: Topiramate is cleared by hemodialysis. Dosage adjustment is necessary to avoid rapid drops in topiramate plasma concentration during hemodialysis (2.6).
- Pregnancy: based on animal data, may cause fetal harm. To enroll in the North American Antiepileptic Drug Pregnancy Registry call 1-800-233-2334 (toll free) (8.1).
- Geriatric Use: Dosage adjustment may be necessary for elderly with impaired renal function (8.5).

See 17 for PATIENT COUNSELING INFORMATION and the FDA-approved Medication Guide.

Revised: December 2009

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Monotherapy Epilepsy
- 1.2 Adjunctive Therapy Epilepsy
- 1.3 Migraine

2 DOSAGE AND ADMINISTRATION

- 2.1 Epilepsy
- 2.2 Migraine
- 2.3 Administration of TOPAMAX® Sprinkle Capsules
- 2.4 Patients with Renal Impairment
- 2.5 Geriatric Patients (Ages 65 Years and Over)
- 2.6 Patients Undergoing Hemodialysis
- 2.7 Patients with Hepatic Disease

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Acute Myopia and Secondary Angle Closure Glaucoma
- 5.2 Oligohidrosis and Hyperthermia
- 5.3 Suicidal Behavior and Ideation
- 5.4 Metabolic Acidosis
- 5.5 Cognitive/Neuropsychiatric Adverse Reactions
- 5.6 Withdrawal of Antiepileptic Drugs (AEDs)
- 5.7 Sudden Unexplained Death in Epilepsy (SUDEP)
- 5.8 Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid [VPA] Use)
- 5.9 Kidney Stones
- 5.10 Paresthesia
- 5.11 Adjustment of Dose in Renal Failure
- 5.12 Decreased Hepatic Function
- 5.13 Monitoring: Laboratory Tests

6 ADVERSE REACTIONS

- 6.1 Monotherapy Epilepsy
- 6.2 Adjunctive Therapy Epilepsy
- 6.3 Incidence in Epilepsy Controlled Clinical Trials – Adjunctive Therapy – Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, and Lennox-Gastaut Syndrome
- 6.4 Other Adverse Reactions Observed During Double-Blind Epilepsy Adjunctive Therapy Trials
- 6.5 Incidence in Study 119 – Add-On Therapy– Adults with Partial Onset Seizures
- 6.6 Other Adverse Reactions Observed During All Epilepsy Clinical Trials
- 6.7 Migraine

- 6.8 Other Adverse Reactions Observed During Migraine Clinical Trials
- 6.9 Postmarketing and Other Experience
- 7 DRUG INTERACTIONS**
 - 7.1 Antiepileptic Drugs
 - 7.2 CNS Depressants
 - 7.3 Oral Contraceptives
 - 7.4 Metformin
 - 7.5 Lithium
 - 7.6 Other Carbonic Anhydrase Inhibitors
- 8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy
 - 8.2 Labor and Delivery
 - 8.3 Nursing Mothers
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
 - 8.6 Race and Gender Effects
 - 8.7 Renal Impairment
 - 8.8 Patients Undergoing Hemodialysis
- 9 DRUG ABUSE AND DEPENDENCE**
 - 9.1 Controlled Substance
 - 9.2 Abuse
 - 9.3 Dependence
- 10 OVERDOSAGE**
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
 - 12.4 Special Populations
 - 12.5 Drug-Drug Interactions
- 13 NON-CLINICAL TOXICOLOGY**
 - 13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility
- 14 CLINICAL STUDIES**
 - 14.1 Monotherapy Epilepsy Controlled Trial
 - 14.2 Migraine Prophylaxis
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
- 17 PATIENT COUNSELING INFORMATION**
 - 17.1 Eye Disorders
 - 17.2 Oligohydrosis and Hyperthermia
 - 17.3 Suicidal Behavior and Ideation
 - 17.4 Metabolic Acidosis
 - 17.5 Interference with Cognitive and Motor Performance
 - 17.6 Hyperammonemia and Encephalopathy
 - 17.7 Kidney Stones
 - 17.8 Use in Pregnancy

*Sections or subsections omitted from the full prescribing information are not listed.

1 INDICATIONS AND USAGE

1.1 Monotherapy Epilepsy

TOPAMAX® (topiramate) Tablets and TOPAMAX® (topiramate capsules) Sprinkle Capsules are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and

effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see *Clinical Studies (14.1)*].

1.2 Adjunctive Therapy Epilepsy

TOPAMAX® (topiramate) Tablets and TOPAMAX® (topiramate capsules) Sprinkle Capsules are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome [see *Clinical Studies (14.2)*].

1.3 Migraine

TOPAMAX® (topiramate) Tablets and TOPAMAX® (topiramate capsules) Sprinkle Capsules are indicated for adults for the prophylaxis of migraine headache [see *Clinical Studies (14.3)*]. The usefulness of TOPAMAX® in the acute treatment of migraine headache has not been studied.

2 DOSAGE AND ADMINISTRATION

2.1 Epilepsy

In the controlled adjunctive (i.e., add-on) trials, no correlation has been demonstrated between trough plasma concentrations of topiramate and clinical efficacy. No evidence of tolerance has been demonstrated in humans. Doses above 400 mg/day (600, 800 or 1,000 mg/day) have not been shown to improve responses in dose-response studies in adults with partial onset seizures.

It is not necessary to monitor topiramate plasma concentrations to optimize TOPAMAX® therapy. On occasion, the addition of TOPAMAX® to phenytoin may require an adjustment of the dose of phenytoin to achieve optimal clinical outcome. Addition or withdrawal of phenytoin and/or carbamazepine during adjunctive therapy with TOPAMAX® may require adjustment of the dose of TOPAMAX®. Because of the bitter taste, tablets should not be broken.

TOPAMAX® can be taken without regard to meals.

Monotherapy Use

The recommended dose for topiramate monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses. Approximately 58% of patients randomized to 400 mg/day achieved this maximal dose in the monotherapy controlled trial; the mean dose achieved in the trial was 275 mg/day. The dose should be achieved by titration according to the following schedule:

| | Morning Dose | Evening Dose |
|--------|--------------|--------------|
| Week 1 | 25 mg | 25 mg |
| Week 2 | 50 mg | 50 mg |
| Week 3 | 75 mg | 75 mg |
| Week 4 | 100 mg | 100 mg |
| Week 5 | 150 mg | 150 mg |
| Week 6 | 200 mg | 200 mg |

Adjunctive Therapy Use

Adults (17 Years of Age and Over) - Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

The recommended total daily dose of TOPAMAX® as adjunctive therapy in adults with partial onset seizures is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as

adjunctive treatment in adults with primary generalized tonic-clonic seizures. It is recommended that therapy be initiated at 25 to 50 mg/day followed by titration to an effective dose in increments of 25 to 50 mg/day every week. Titrating in increments of 25 mg/day every week may delay the time to reach an effective dose. Daily doses above 1,600 mg have not been studied.

In the study of primary generalized tonic-clonic seizures the initial titration rate was slower than in previous studies; the assigned dose was reached at the end of 8 weeks [see *Clinical Studies (14.1)*].

Pediatric Patients (Ages 2 - 16 Years) – Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

The recommended total daily dose of TOPAMAX® (topiramate) as adjunctive therapy for pediatric patients with partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2 week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome.

In the study of primary generalized tonic-clonic seizures the initial titration rate was slower than in previous studies; the assigned dose of 6 mg/kg/day was reached at the end of 8 weeks [see *Clinical Studies (14.1)*].

2.2 Migraine

The recommended total daily dose of TOPAMAX® as treatment for adults for prophylaxis of migraine headache is 100 mg/day administered in two divided doses. The recommended titration rate for topiramate for migraine prophylaxis to 100 mg/day is:

| | Morning Dose | Evening Dose |
|--------|--------------|--------------|
| Week 1 | None | 25 mg |
| Week 2 | 25 mg | 25 mg |
| Week 3 | 25 mg | 50 mg |
| Week 4 | 50 mg | 50 mg |

Dose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used.

TOPAMAX® can be taken without regard to meals.

2.3 Administration of TOPAMAX® Sprinkle Capsules

TOPAMAX® (topiramate capsules) Sprinkle Capsules may be swallowed whole or may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (teaspoon) of soft food. This drug/food mixture should be swallowed immediately and not chewed. It should not be stored for future use.

2.4 Patients with Renal Impairment

In renally impaired subjects (creatinine clearance less than 70 mL/min/1.73 m²), one-half of the usual adult dose is recommended. Such patients will require a longer time to reach steady-state at each dose.

2.5 Geriatric Patients (Ages 65 Years and Over)

Dosage adjustment may be indicated in the elderly patient when impaired renal function (creatinine clearance rate <70 mL/min/1.73 m²) is evident [see *Clinical Pharmacology (12.3)*].

2.6 Patients Undergoing Hemodialysis

Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to fall below that required to maintain an anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed.

2.7 Patients with Hepatic Disease

In hepatically impaired patients, topiramate plasma concentrations may be increased. The mechanism is not well understood.

3 DOSAGE FORMS AND STRENGTHS

TOPAMAX® (topiramate) Tablets are available as debossed, coated, round tablets in the following strengths and colors:

- 25 mg cream (debossed "OMN" on one side; "25" on the other)
- 50 mg light-yellow (debossed "OMN" on one side; "50" on the other)
- 100 mg yellow (debossed "OMN" on one side; "100" on the other)
- 200 mg salmon (debossed "OMN" on one side; "200" on the other)

TOPAMAX® (topiramate capsules) Sprinkle Capsules contain small, white to off white spheres. The gelatin capsules are white and clear.

They are marked as follows:

- 15 mg capsule with "TOP" and "15 mg" on the side
- 25 mg capsule with "TOP" and "25 mg" on the side

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Acute Myopia and Secondary Angle Closure Glaucoma

A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving TOPAMAX®. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness) and increased intraocular pressure. Mydriasis may or may not be present. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating TOPAMAX® therapy. In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in pediatric patients as well as adults. The primary treatment to reverse symptoms is discontinuation of TOPAMAX® as rapidly as possible, according to the judgment of the treating physician. Other measures, in conjunction with discontinuation of TOPAMAX®, may be helpful.

Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.

5.2 Oligohidrosis and Hyperthermia

Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with TOPAMAX® use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures.

The majority of the reports have been in pediatric patients. Patients, especially pediatric patients, treated with TOPAMAX® should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Caution should be used when TOPAMAX® is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.

5.3 Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including TOPAMAX®, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 1 shows absolute and relative risk by indication for all evaluated AEDs.

Table 1: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

| Indication | Placebo Patients with Events per 1000 Patients | Drug Patients with Events per 1000 Patients | Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients | Risk Difference: Additional Drug Patients with Events per 1000 Patients |
|-------------|--|---|--|---|
| Epilepsy | 1.0 | 3.4 | 3.5 | 2.4 |
| Psychiatric | 5.7 | 8.5 | 1.5 | 2.9 |
| Other | 1.0 | 1.8 | 1.9 | 0.9 |
| Total | 2.4 | 4.3 | 1.8 | 1.9 |

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing TOPAMAX® or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior or the emergence of suicidal thoughts, behavior or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

5.4 Metabolic Acidosis

Hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) is associated with topiramate treatment. This metabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase. Such electrolyte imbalance has been observed with the use of topiramate in placebo-controlled clinical trials and in the post-marketing period. Generally, topiramate-induced metabolic acidosis occurs early in treatment although cases can occur at any time during treatment. Bicarbonate decrements are usually mild-moderate (average decrease of 4 mEq/L at daily doses of 400 mg in adults and at approximately 6 mg/kg/day in pediatric patients); rarely, patients can experience severe decrements to values below 10 mEq/L. Conditions or therapies that predispose patients to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, ketogenic diet or specific drugs) may be additive to the bicarbonate lowering effects of topiramate.

In adults, the incidence of persistent treatment-emergent decreases in serum bicarbonate (levels of <20 mEq/L at two consecutive visits or at the final visit) in controlled clinical trials for adjunctive treatment of epilepsy was 32% for 400 mg/day, and 1% for placebo. Metabolic acidosis has been observed at doses as low as 50 mg/day. The incidence of persistent treatment-emergent decreases in serum bicarbonate in adults in the epilepsy controlled clinical trial for monotherapy was 15% for 50 mg/day and 25% for 400 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in the adjunctive therapy trials was 3% for 400 mg/day, and 0% for placebo and in the monotherapy trial was 1% for 50 mg/day and 7% for 400 mg/day. Serum bicarbonate levels have not been systematically evaluated at daily doses greater than 400 mg/day.

In pediatric patients (2-16 years of age), the incidence of persistent treatment-emergent decreases in serum bicarbonate in placebo-controlled trials for adjunctive treatment of Lennox-Gastaut syndrome or refractory partial onset seizures was 67% for TOPAMAX® (at approximately 6 mg/kg/day), and 10% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in these trials was 11% for TOPAMAX® and 0% for placebo. Cases of moderately severe metabolic acidosis have been reported in patients as young as 5 months old, especially at daily doses above 5 mg/kg/day.

Although not approved for use in patients under 2 years of age with partial onset seizures, a controlled trial that examined this population revealed that topiramate produced a metabolic acidosis that is notably greater in magnitude than that observed in controlled trials in older children and adults. The mean treatment difference (25 mg/kg/d topiramate-placebo) was -5.9 mEq/L for bicarbonate. The incidence of metabolic acidosis (defined by a serum bicarbonate <20 mEq/L) was 0% for placebo, 30% for 5 mg/kg/d, 50% for 15 mg/kg/d, and 45% for 25 mg/kg/d [see *Pediatric Use (8.4)*].

In pediatric patients (10 years up to 16 years of age), the incidence of persistent treatment-emergent decreases in serum bicarbonate in the epilepsy controlled clinical trial for monotherapy was 7% for 50 mg/day and 20% for 400 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in this trial was 4% for 50 mg/day and 4% for 400 mg/day. The incidence of persistent treatment-emergent decreases in serum bicarbonate in placebo-controlled trials for adults for prophylaxis of migraine was 44% for 200 mg/day, 39% for 100 mg/day, 23% for 50 mg/day, and 7% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in these trials was 11% for 200 mg/day, 9% for 100 mg/day, 2% for 50 mg/day, and <1% for placebo.

Some manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelae including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis, and may also result in osteomalacia (referred to as rickets in pediatric patients) and/or osteoporosis with an increased risk for fractures. Chronic metabolic acidosis in pediatric patients may also reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth

and bone-related sequelae has not been systematically investigated in long-term, placebo-controlled trials. Long-term, open-label treatment of infants/toddlers, with intractable partial epilepsy, for up to 1 year, showed reductions from baseline in Z SCORES for length, weight, and head circumference compared to age and sex-matched normative data, although these patients with epilepsy are likely to have different growth rates than normal infants. Reductions in Z SCORES for length and weight were correlated to the degree of acidosis [see *Pediatric Use (8.4)*].

Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent acidosis, alkali treatment should be considered.

5.5 Cognitive/Neuropsychiatric Adverse Reactions

Adverse reactions most often associated with the use of TOPAMAX® were related to the central nervous system and were observed in both the epilepsy and migraine populations. In adults, the most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g. confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-finding difficulties); 2) Psychiatric/behavioral disturbances (e.g. depression or mood problems); and 3) Somnolence or fatigue.

Adult Patients

Cognitive-Related Dysfunction

The majority of cognitive-related adverse reactions were mild to moderate in severity, and they frequently occurred in isolation. Rapid titration rate and higher initial dose were associated with higher incidences of these reactions. Many of these reactions contributed to withdrawal from treatment [see *Adverse Reactions (6)*].

In the add-on epilepsy controlled trials (using rapid titration such as 100-200 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse reactions was 42% for 200 mg/day, 41% for 400 mg/day, 52% for 600 mg/day, 56% for 800 and 1000 mg/day, and 14% for placebo. These dose-related adverse reactions began with a similar frequency in the titration or in the maintenance phase, although in some patients the events began during titration and persisted into the maintenance phase. Some patients who experienced one or more cognitive-related adverse reactions in the titration phase had a dose-related recurrence of these reactions in the maintenance phase.

In the monotherapy epilepsy controlled trial, the proportion of patients who experienced one or more cognitive-related adverse reactions was 19% for TOPAMAX® 50 mg/day and 26% for 400 mg/day.

In the 6-month migraine prophylaxis controlled trials using a slower titration regimen (25 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse reactions was 19% for TOPAMAX® 50 mg/day, 22% for 100 mg/day (the recommended dose), 28% for 200 mg/day, and 10% for placebo. These dose-related adverse reactions typically began in the titration phase and often persisted into the maintenance phase, but infrequently began in the maintenance phase. Some patients experienced a recurrence of one or more of these cognitive adverse reactions and this recurrence was typically in the titration phase. A relatively small proportion of topiramate-treated patients experienced more than one concurrent cognitive adverse reaction.

The most common cognitive adverse reactions occurring together included difficulty with memory along with difficulty with concentration/attention, difficulty with memory along with language problems, and difficulty with concentration/attention along with language problems. Rarely, topiramate-treated patients experienced three concurrent cognitive reactions.

Psychiatric/Behavioral Disturbances

Psychiatric/behavioral disturbances (depression or mood) were dose-related for both the epilepsy and migraine populations [see *Warnings and Precautions (5.3)*].

Somnolence/Fatigue

Somnolence and fatigue were the adverse reactions most frequently reported during clinical trials of TOPAMAX® for adjunctive epilepsy. For the adjunctive epilepsy population, the incidence of somnolence did not differ substantially between 200 mg/day and 1000 mg/day, but the incidence of fatigue was dose-related and increased at dosages above 400 mg/day. For the monotherapy epilepsy population in the 50 mg/day and 400 mg/day groups, the incidence of somnolence was dose-related (9% for the 50 mg/day group and 15% for the 400 mg/day group) and the incidence of fatigue was comparable in both treatment groups (14% each). For the migraine population, fatigue and somnolence were dose-related and more common in the titration phase.

Additional nonspecific CNS events commonly observed with topiramate in the add-on epilepsy population include dizziness or ataxia.

Pediatric Patients

In double-blind adjunctive therapy and monotherapy epilepsy clinical studies, the incidences of cognitive/neuropsychiatric adverse reactions in pediatric patients were generally lower than observed in adults. These reactions included psychomotor slowing, difficulty with concentration/attention, speech disorders/related speech problems and language problems. The most frequently reported neuropsychiatric reactions in pediatric patients during adjunctive therapy double-blind studies were somnolence and fatigue. The most frequently reported neuropsychiatric reactions in pediatric patients in the 50 mg/day and 400 mg/day groups during the monotherapy double-blind study were headache, dizziness, anorexia, and somnolence.

No patients discontinued treatment due to any adverse events in the adjunctive epilepsy double-blind trials. In the monotherapy epilepsy double-blind trial, 1 pediatric patient (2%) in the 50 mg/day group and 7 pediatric patients (12%) in the 400 mg/day group discontinued treatment due to any adverse events. The most common adverse reaction associated with discontinuation of therapy was difficulty with concentration/attention; all occurred in the 400 mg/day group.

5.6 Withdrawal of Antiepileptic Drugs (AEDs)

In patients with or without a history of seizures or epilepsy, antiepileptic drugs including TOPAMAX® should be gradually withdrawn to minimize the potential for seizures or increased seizure frequency [see *Clinical Studies (14)*]. In situations where rapid withdrawal of TOPAMAX® is medically required, appropriate monitoring is recommended.

5.7 Sudden Unexplained Death in Epilepsy (SUDEP)

During the course of premarketing development of TOPAMAX® (topiramate) Tablets, 10 sudden and unexplained deaths were recorded among a cohort of treated patients (2,796 subject years of exposure). This represents an incidence of 0.0035 deaths per patient year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving TOPAMAX® (ranging from 0.0005 for the general population of patients with epilepsy, to 0.003 for a clinical trial population similar to that in the TOPAMAX® program, to 0.005 for patients with refractory epilepsy).

5.8 Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid [VPA] Use)

Hyperammonemia/Encephalopathy Without Concomitant Valproic Acid (VPA)

Topiramate treatment has produced hyperammonemia (in some instances dose-related) in clinical investigational programs of adolescents (12-16 years) who were treated with topiramate monotherapy for migraine prophylaxis (incidence above normal, 22% for placebo, 26% for 50 mg/day, 41% for 100 mg daily) and in very young pediatric patients (1-24 months) who were treated with adjunctive topiramate for partial onset epilepsy (8% for placebo, 10% for 5 mg/kg/day, 0% for 15 mg/kg/day, 9% for 25 mg/kg/day). Topiramate is not approved as monotherapy for migraine prophylaxis in adolescent patients or as adjunctive treatment of partial onset seizures in pediatric patients less than 2 years old. In some patients, ammonia was markedly increased ($\geq 50\%$ above upper limit of normal). In the adolescent patients, the incidence of markedly increased hyperammonemia was 6% for placebo, 6% for 50 mg, and 12% for 100 mg topiramate daily. The hyperammonemia associated with topiramate treatment occurred with and without encephalopathy in placebo-controlled trials, and in an open-label, extension trial. Dose-related hyperammonemia was also observed in the extension trial in pediatric patients up to 2 years old. Clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting.

Hyperammonemia with and without encephalopathy has also been observed in post-marketing reports in patients who were taking topiramate without concomitant valproic acid (VPA).

Hyperammonemia/Encephalopathy With Concomitant Valproic Acid (VPA)

Concomitant administration of topiramate and valproic acid (VPA) has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone based upon post-marketing reports. Although hyperammonemia may be asymptomatic, clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. In most cases, symptoms and signs abated with discontinuation of either drug. This adverse reaction is not due to a pharmacokinetic interaction.

Although topiramate is not indicated for use in infants/toddlers (1-24 months) VPA clearly produced a dose-related increase in the incidence of treatment-emergent hyperammonemia (above the upper limit of normal, 0% for placebo, 12% for 5 mg/kg/day, 7% for 15 mg/kg/day, 17% for 25 mg/kg/day) in an investigational program. Markedly increased, dose-related hyperammonemia (0% for placebo

and 5 mg/kg/day, 7% for 15 mg/kg/day, 8% for 25 mg/kg/day) also occurred in these infants/toddlers. Dose-related hyperammonemia was similarly observed in a long-term, extension trial in these very young, pediatric patients [see *Use in Specific Populations* (8.4)].

Hyperammonemia with and without encephalopathy has also been observed in post-marketing reports in patients taking topiramate with valproic acid (VPA).

The hyperammonemia associated with topiramate treatment appears to be more common when topiramate is used concomitantly with VPA.

Monitoring for Hyperammonemia

Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may be at an increased risk for hyperammonemia with or without encephalopathy. Although not studied, topiramate treatment or an interaction of concomitant topiramate and valproic acid treatment may exacerbate existing defects or unmask deficiencies in susceptible persons.

In patients who develop unexplained lethargy, vomiting, or changes in mental status associated with any topiramate treatment, hyperammonemic encephalopathy should be considered and an ammonia level should be measured.

5.9 Kidney Stones

A total of 32/2,086 (1.5%) of adults exposed to topiramate during its adjunctive epilepsy therapy development reported the occurrence of kidney stones, an incidence about 2 to 4 times greater than expected in a similar, untreated population. In the double-blind monotherapy epilepsy study, a total of 4/319 (1.3%) of adults exposed to topiramate reported the occurrence of kidney stones. As in the general population, the incidence of stone formation among topiramate treated patients was higher in men. Kidney stones have also been reported in pediatric patients. During long-term (up to 1 year) topiramate treatment in an open-label extension study of 284 pediatric patients 1-24 months old with epilepsy, 7% developed kidney or bladder stones that were diagnosed clinically or by sonogram. Topiramate is not approved for pediatric patients less than 2 years old [see *Pediatric Use* (8.4)].

An explanation for the association of TOPAMAX® and kidney stones may lie in the fact that topiramate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) can promote stone formation by reducing urinary citrate excretion and by increasing urinary pH [see *Warnings and Precautions* (5.4)]. The concomitant use of TOPAMAX® with any other drug producing metabolic acidosis, or potentially in patients on a ketogenic diet may create a physiological environment that increases the risk of kidney stone formation, and should therefore be avoided.

Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce new stone formation.

5.10 Paresthesia

Paresthesia (usually tingling of the extremities), an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of TOPAMAX®. Paresthesia was more frequently reported in the monotherapy epilepsy trials and migraine prophylaxis trials than in the adjunctive therapy epilepsy trials. In the majority of instances, paresthesia did not lead to treatment discontinuation.

5.11 Adjustment of Dose in Renal Failure

The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Dosage adjustment may be required in patients with reduced renal function [see *Dosage and Administration* (2)].

5.12 Decreased Hepatic Function

In hepatically impaired patients, topiramate should be administered with caution as the clearance of topiramate may be decreased.

5.13 Monitoring: Laboratory Tests

Topiramate treatment was associated with changes in several clinical laboratory analytes in randomized, double-blind, placebo-controlled studies.

Topiramate treatment causes non-anion gap, hyperchloremic, metabolic acidosis manifested by a decrease in serum bicarbonate and increase in serum chloride. Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended [see *Warnings and Precautions* (5.4)].

Controlled trials of adjunctive topiramate treatment of adults for partial onset seizures showed an increased incidence of markedly decreased serum phosphorus (6% topiramate, 2% placebo), markedly increased serum alkaline phosphatase (3% topiramate, 1% placebo), and decreased serum potassium (0.4 % topiramate, 0.1 % placebo). The clinical significance of these abnormalities has not been clearly established.

Changes in several clinical laboratory laboratories (increased creatinine, BUN, alkaline phosphatase, total protein, total eosinophil count and decreased potassium) have been observed in a clinical investigational program in very young (<2 years) pediatric patients who were treated with adjunctive topiramate for partial onset seizures [see *Pediatric Use* (8.4)].

Topiramate treatment produced a dose-related increased shift in serum creatinine from normal at baseline to an increased value at the end of 4 months treatment in adolescent patients (ages 12-16 years) who were treated for migraine prophylaxis in a double-blind, placebo-controlled study.

Topiramate treatment with or without concomitant valproic acid (VPA) can cause hyperammonemia with or without encephalopathy [see *Warnings and Precautions* (5.8)].

6 ADVERSE REACTIONS

The data described in the following section were obtained using TOPAMAX® (topiramate) Tablets.

6.1 Monotherapy Epilepsy

The adverse reactions in the controlled trial that occurred most commonly in adults in the 400 mg/day group and at a rate higher than the 50 mg/day group were: paresthesia, weight decrease, somnolence, anorexia, dizziness, and difficulty with memory NOS [see *Table 2*].

The adverse reactions in the controlled trial that occurred most commonly in children (10 years up to 16 years of age) in the 400 mg/day group and at a rate higher than the 50 mg/day group were: weight decrease, upper respiratory tract infection, paresthesia, anorexia, diarrhea, and mood problems [see *Table 3*].

Approximately 21% of the 159 adult patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse reactions. Adverse reactions associated with discontinuing therapy ($\geq 2\%$) included depression, insomnia, difficulty with memory (NOS), somnolence, paresthesia, psychomotor slowing, dizziness, and nausea.

Approximately 12% of the 57 pediatric patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse reactions. Adverse reactions associated with discontinuing therapy ($\geq 5\%$) included difficulty with concentration/attention.

The prescriber should be aware that these data cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during the clinical study. Similarly, the cited frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. Inspection of these frequencies, however, does provide the prescribing physician with a basis to estimate the relative contribution of drug and non-drug factors to the adverse reactions incidences in the population studied.

Table 2: Incidence of Treatment-Emergent Adverse Reaction in the Monotherapy Epilepsy Trial in Adults^a Where Incidence Was at Least 2% in the 400 mg/day Topiramate Group and Greater Than the Rate in the 50 mg/day Topiramate Group

| Body System/ Adverse Reaction | TOPAMAX® Dosage (mg/day) | |
|--|-----------------------------|----------------|
| | 50 (N=160) | 400 (N=159) |
| Body as a Whole—General Disorders | | |
| Asthenia | 4 | 6 |
| Leg Pain | 2 | 3 |
| Chest Pain | 1 | 2 |
| Central & Peripheral Nervous System Disorders | | |
| Paresthesia | 21 | 40 |
| Dizziness | 13 | 14 |
| Hypoaesthesia | 4 | 5 |
| Ataxia | 3 | 4 |
| Hypertonia | 0 | 3 |
| Gastro-Intestinal System Disorders | | |
| Diarrhea | 5 | 6 |
| Constipation | 1 | 4 |
| Gastritis | 0 | 3 |
| Dry Mouth | 1 | 3 |
| Gastroesophageal Reflux | 1 | 2 |
| Liver and Biliary System Disorders | | |
| Gamma-GT Increased | 1 | 3 |
| Metabolic and Nutritional Disorders | | |
| Weight Decrease | 6 | 16 |
| Psychiatric Disorders | | |
| Somnolence | 9 | 15 |
| Anorexia | 4 | 14 |
| Difficulty with Memory NOS | 5 | 10 |
| Insomnia | 8 | 9 |
| Depression | 7 | 9 |
| Difficulty with Concentration/Attention | 7 | 8 |
| Anxiety | 4 | 6 |
| Psychomotor Slowing | 3 | 5 |
| Mood Problems | 2 | 5 |
| Confusion | 3 | 4 |
| Cognitive Problem NOS | 1 | 4 |
| Libido Decreased | 0 | 3 |
| Reproductive Disorders, Female | | |
| Vaginal Hemorrhage | 0 | 3 |

Table 2: Incidence of Treatment-Emergent Adverse Reaction in the Monotherapy Epilepsy Trial in Adults^a Where Incidence Was at Least 2% in the 400 mg/day Topiramate Group and Greater Than the Rate in the 50 mg/day Topiramate Group (continued)

| Body System/ Adverse Reaction | TOPAMAX® Dosage (mg/day) | |
|--|-----------------------------|----------------|
| | 50 (N=160) | 400 (N=159) |
| Red Blood Cell Disorders | | |
| Anemia | 1 | 2 |
| Resistance Mechanism Disorders | | |
| Infection Viral | 6 | 8 |
| Infection | 2 | 3 |
| Respiratory System Disorders | | |
| Bronchitis | 3 | 4 |
| Rhinitis | 2 | 4 |
| Dyspnea | 1 | 2 |
| Skin and Appendages Disorders | | |
| Rash | 1 | 4 |
| Pruritus | 1 | 4 |
| Acne | 2 | 3 |
| Special Senses Other, Disorders | | |
| Taste Perversion | 3 | 5 |
| Urinary System Disorders | | |
| Cystitis | 1 | 3 |
| Renal Calculus | 0 | 3 |
| Urinary Tract Infection | 1 | 2 |
| Dysuria | 0 | 2 |
| Micturition Frequency | 0 | 2 |

^a Values represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.

Table 3: Incidence of Treatment-Emergent Adverse Reactions in the Monotherapy Epilepsy Trial in Pediatric Patients (Ages 10 up to 16 Years)^a Where Incidence Was at Least 5% in the 400 mg/day Topiramate Group and Greater Than the Rate in the 50 mg/day Topiramate Group

| Body System/ Adverse Reaction | TOPAMAX® Dosage (mg/day) | |
|--|-----------------------------|---------------|
| | 50 (N=57) | 400 (N=57) |
| Body as a Whole—General Disorders | | |
| Fever | 0 | 9 |
| Central & Peripheral Nervous System Disorders | | |
| Paresthesia | 2 | 16 |
| Gastro-Intestinal System Disorders | | |
| Diarrhea | 5 | 11 |
| Metabolic and Nutritional Disorders | | |
| Weight Decrease | 7 | 21 |
| Psychiatric Disorders | | |
| Anorexia | 11 | 14 |
| Mood Problems | 2 | 11 |
| Difficulty with Concentration/Attention | 4 | 9 |
| Cognitive Problems NOS | 0 | 7 |
| Nervousness | 4 | 5 |

Table 3: Incidence of Treatment-Emergent Adverse Reactions in the Monotherapy Epilepsy Trial in Pediatric Patients (Ages 10 up to 16 Years)^a Where Incidence Was at Least 5% in the 400 mg/day Topiramate Group and Greater Than the Rate in the 50 mg/day Topiramate Group (continued)

| Body System/ Adverse Reaction | TOPAMAX® Dosage (mg/day) | |
|---------------------------------------|-----------------------------|---------------|
| | 50 (N=57) | 400 (N=57) |
| Resistance Mechanism Disorders | | |
| Infection Viral | 4 | 9 |
| Infection | 2 | 7 |
| Respiratory System Disorders | | |
| Upper Respiratory Tract Infection | 16 | 18 |
| Rhinitis | 2 | 7 |
| Bronchitis | 2 | 7 |
| Sinusitis | 2 | 5 |
| Skin and Appendages Disorders | | |
| Alopecia | 2 | 5 |

^a Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one adverse event during the study and can be included in more than one adverse event category.

6.2 Adjunctive Therapy Epilepsy

The most commonly observed adverse reactions associated with the use of topiramate at dosages of 200 to 400 mg/day in controlled trials in adults with partial onset seizures, primary generalized tonic-clonic seizures, or Lennox-Gastaut syndrome, that were seen at greater frequency in topiramate-treated patients and did not appear to be dose-related were: somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia and diplopia [see *Table 4*]. The most common dose-related adverse reactions at dosages of 200 to 1,000 mg/day were: fatigue, nervousness, difficulty with concentration or attention, confusion, depression, anorexia, language problems, anxiety, mood problems, and weight decrease [see *Table 6*].

Adverse reactions associated with the use of topiramate at dosages of 5 to 9 mg/kg/day in controlled trials in pediatric patients with partial onset seizures, primary generalized tonic-clonic seizures, or Lennox-Gastaut syndrome, that were seen at greater frequency in topiramate-treated patients were: fatigue, somnolence, anorexia, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease [see *Table 7*].

In controlled clinical trials in adults, 11% of patients receiving topiramate 200 to 400 mg/day as adjunctive therapy discontinued due to adverse reactions. This rate appeared to increase at dosages above 400 mg/day. Adverse events associated with discontinuing therapy included somnolence, dizziness, anxiety, difficulty with concentration or attention, fatigue, and paresthesia and increased at dosages above 400 mg/day. None of the pediatric patients who received topiramate adjunctive therapy at 5 to 9 mg/kg/day in controlled clinical trials discontinued due to adverse reactions.

Approximately 28% of the 1,757 adults with epilepsy who received topiramate at dosages of 200 to 1,600 mg/day in clinical studies discontinued treatment because of adverse reactions; an individual patient could have reported more than one adverse reaction. These adverse reactions were: psychomotor slowing (4.0%), difficulty with memory (3.2%), fatigue (3.2%), confusion (3.1%), somnolence (3.2%), difficulty with concentration/attention (2.9%), anorexia (2.7%), depression (2.6%), dizziness (2.5%), weight decrease (2.5%), nervousness (2.3%), ataxia (2.1%), and paresthesia (2.0%). Approximately 11% of the 310 pediatric patients who received topiramate at dosages up to 30 mg/kg/day discontinued due to adverse reactions. Adverse reactions associated with discontinuing therapy included aggravated convulsions (2.3%), difficulty with concentration/attention (1.6%), language problems (1.3%), personality disorder (1.3%), and somnolence (1.3%).

6.3 Incidence in Epilepsy Controlled Clinical Trials – Adjunctive Therapy – Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, and Lennox-Gastaut Syndrome

Table 4 lists treatment-emergent adverse reactions that occurred in at least 1% of adults treated with 200 to 400 mg/day topiramate in controlled trials that were numerically more common at this dose than in the patients treated with placebo. In general, most patients who experienced adverse reactions during the first eight weeks of these trials no longer experienced them by their last visit. *Table 7* lists treatment-emergent adverse reactions that occurred in at least 1% of pediatric patients treated with 5 to 9 mg/kg topiramate in controlled trials that were numerically more common than in patients treated with placebo.

The prescriber should be aware that these data were obtained when TOPAMAX® was added to concurrent antiepileptic drug therapy and cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. Inspection of these frequencies, however, does provide the prescribing physician with a basis to estimate the relative contribution of drug and non-drug factors to the adverse reaction incidences in the population studied.

6.4 Other Adverse Reactions Observed During Double-Blind Epilepsy Adjunctive Therapy Trials

Other adverse reactions that occurred in more than 1% of adults treated with 200 to 400 mg of topiramate in placebo-controlled epilepsy trials but with equal or greater frequency in the placebo group were: headache, injury, anxiety, rash, pain, convulsions aggravated, coughing, fever, diarrhea, vomiting, muscle weakness, insomnia, personality disorder, dysmenorrhea, upper respiratory tract infection, and eye pain.

Table 4: Incidence of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On Epilepsy Trials in Adults^{a,b} Where Incidence Was > 1% in Any Topiramate Group and Greater Than the Rate in Placebo-Treated Patients

| Body System/ Adverse Reaction ^c | TOPAMAX® Dosage (mg/day) | | |
|---|-----------------------------|--------------------|----------------------|
| | Placebo (N=291) | 200-400 (N=183) | 600-1,000 (N=414) |
| Body as a Whole— | | | |
| General Disorders | | | |
| Fatigue | 13 | 15 | 30 |
| Asthenia | 1 | 6 | 3 |
| Back Pain | 4 | 5 | 3 |
| Chest Pain | 3 | 4 | 2 |
| Influenza-Like Symptoms | 2 | 3 | 4 |
| Leg Pain | 2 | 2 | 4 |
| Hot Flushes | 1 | 2 | 1 |
| Allergy | 1 | 2 | 3 |
| Edema | 1 | 2 | 1 |
| Body Odor | 0 | 1 | 0 |
| Rigors | 0 | 1 | <1 |
| Central & Peripheral | | | |
| Nervous System Disorders | | | |
| Dizziness | 15 | 25 | 32 |
| Ataxia | 7 | 16 | 14 |
| Speech Disorders/Related | | | |
| Speech Problems | 2 | 13 | 11 |
| Paresthesia | 4 | 11 | 19 |
| Nystagmus | 7 | 10 | 11 |
| Tremor | 6 | 9 | 9 |
| Language Problems | 1 | 6 | 10 |
| Coordination Abnormal | 2 | 4 | 4 |
| Hypoaesthesia | 1 | 2 | 1 |
| Gait Abnormal | 1 | 3 | 2 |
| Muscle Contractions | | | |
| Involuntary | 1 | 2 | 2 |
| Stupor | 0 | 2 | 1 |
| Vertigo | 1 | 1 | 2 |
| Gastro-Intestinal | | | |
| System Disorders | | | |
| Nausea | 8 | 10 | 12 |
| Dyspepsia | 6 | 7 | 6 |
| Abdominal Pain | 4 | 6 | 7 |
| Constipation | 2 | 4 | 3 |
| Gastroenteritis | 1 | 2 | 1 |
| Dry Mouth | 1 | 2 | 4 |
| Gingivitis | <1 | 1 | 1 |
| GI Disorder | <1 | 1 | 0 |
| Hearing and Vestibular | | | |
| Disorders | | | |
| Hearing Decreased | 1 | 2 | 1 |
| Metabolic and Nutritional | | | |
| Disorders | | | |
| Weight Decrease | 3 | 9 | 13 |
| Muscle-Skeletal System | | | |
| Disorders | | | |
| Myalgia | 1 | 2 | 2 |
| Skeletal Pain | 0 | 1 | 0 |
| Platelet, Bleeding, & | | | |
| Clotting Disorders | | | |
| Epistaxis | 1 | 2 | 1 |
| Psychiatric Disorders | | | |
| Somnolence | 12 | 29 | 28 |
| Nervousness | 6 | 16 | 19 |

Table 4: Incidence of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On Epilepsy Trials in Adults^{a,b} Where Incidence Was > 1% in Any Topiramate Group and Greater Than the Rate in Placebo-Treated Patients (continued)

| Body System/ Adverse Reaction ^c | TOPAMAX® Dosage (mg/day) | | |
|---|-----------------------------|--------------------|----------------------|
| | Placebo (N=291) | 200-400 (N=183) | 600-1,000 (N=414) |
| Psychiatric Disorders | | | |
| Psychomotor Slowing | 2 | 13 | 21 |
| Difficulty with Memory | 3 | 12 | 14 |
| Anorexia | 4 | 10 | 12 |
| Confusion | 5 | 11 | 14 |
| Depression | 5 | 5 | 13 |
| Difficulty with | | | |
| Concentration/Attention | 2 | 6 | 14 |
| Mood Problems | 2 | 4 | 9 |
| Agitation | 2 | 3 | 3 |
| Aggressive Reaction | 2 | 3 | 3 |
| Emotional Lability | 1 | 3 | 3 |
| Cognitive Problems | 1 | 3 | 3 |
| Libido Decreased | 1 | 2 | <1 |
| Apathy | 1 | 1 | 3 |
| Depersonalization | 1 | 1 | 2 |
| Reproductive Disorders, Female | | | |
| Breast Pain | 2 | 4 | 0 |
| Amenorrhea | 1 | 2 | 2 |
| Menorrhagia | 0 | 2 | 1 |
| Menstrual Disorder | 1 | 2 | 1 |
| Reproductive Disorders, Male | | | |
| Prostatic Disorder | <1 | 2 | 0 |
| Resistance Mechanism | | | |
| Disorders | | | |
| Infection | 1 | 2 | 1 |
| Infection Viral | 1 | 2 | <1 |
| Moniliasis | <1 | 1 | 0 |
| Respiratory System Disorders | | | |
| Pharyngitis | 2 | 6 | 3 |
| Rhinitis | 6 | 7 | 6 |
| Sinusitis | 4 | 5 | 6 |
| Dyspnea | 1 | 1 | 2 |
| Skin and Appendages | | | |
| Disorders | | | |
| Skin Disorder | <1 | 2 | 1 |
| Sweating Increased | <1 | 1 | <1 |
| Rash Erythematous | <1 | 1 | <1 |
| Special Sense Other, | | | |
| Disorders | | | |
| Taste Perversion | 0 | 2 | 4 |
| Urinary System Disorders | | | |
| Hematuria | 1 | 2 | <1 |
| Urinary Tract Infection | 1 | 2 | 3 |
| Micturition Frequency | 1 | 1 | 2 |
| Urinary Incontinence | <1 | 2 | 1 |
| Urine Abnormal | 0 | 1 | <1 |
| Vision Disorders | | | |
| Vision Abnormal | 2 | 13 | 10 |
| Diplopia | 5 | 10 | 10 |
| White Cell and RES Disorders | | | |
| Leukopenia | 1 | 2 | 1 |

^a Patients in these add-on/ adjunctive trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to TOPAMAX® or placebo.

^b Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.

^c Adverse reactions reported by at least 1% of patients in the TOPAMAX[®] 200-400 mg/day group and more common than in the placebo group are listed in this table.

6.5 Incidence in Study 119 – Add-On Therapy– Adults with Partial Onset Seizures

Study 119 was a randomized, double-blind, add-on/adjunctive, placebo-controlled, parallel group study with 3 treatment arms: 1) placebo; 2) topiramate 200 mg/day with a 25 mg/day starting dose, increased by 25 mg/day each week for 8 weeks until the 200 mg/day maintenance dose was reached; and 3) topiramate 200 mg/day with a 50 mg/day starting dose, increased by 50 mg/day each week for 4 weeks until the 200 mg/day maintenance dose was reached. All patients were maintained on concomitant carbamazepine with or without another concomitant antiepileptic drug.

The incidence of adverse reactions (*Table 5*) did not differ significantly between the 2 topiramate regimens. Because the frequencies of adverse reactions reported in this study were markedly lower than those reported in the previous epilepsy studies, they cannot be directly compared with data obtained in other studies.

Table 5: Incidence of Treatment-Emergent Adverse Reactions in Study 119^{a,b} Where Incidence Was $\geq 2\%$ in the Topiramate Group and Greater Than the Rate in Placebo-Treated Patients

| Body System/ Adverse Reaction ^c | Placebo (N=92) | TOPAMAX [®] Dosage (mg/day) |
|--|-------------------|---|
| | | 200 (N=171) |
| Body as a Whole– General Disorders | | |
| Fatigue | 4 | 9 |
| Chest Pain | 1 | 2 |
| Cardiovascular Disorders, General | | |
| Hypertension | 0 | 2 |
| Central & Peripheral Nervous System Disorders | | |
| Paresthesia | 2 | 9 |
| Dizziness | 4 | 7 |
| Tremor | 2 | 3 |
| Hypoesthesia | 0 | 2 |
| Leg Cramps | 0 | 2 |
| Language Problems | 0 | 2 |
| Gastro-Intestinal System Disorders | | |
| Abdominal Pain | 3 | 5 |
| Constipation | 0 | 4 |
| Diarrhea | 1 | 2 |
| Dyspepsia | 0 | 2 |
| Dry Mouth | 0 | 2 |
| Hearing and Vestibular Disorders | | |
| Tinnitus | 0 | 2 |
| Metabolic and Nutritional Disorders | | |
| Weight Decrease | 4 | 8 |

Table 5: Incidence of Treatment-Emergent Adverse Reactions in Study 119^{a,b} Where Incidence Was $\geq 2\%$ in the Topiramate Group and Greater Than the Rate in Placebo-Treated Patients (continued)

| Body System/ Adverse Reaction ^c | Placebo | TOPAMAX [®] Dosage (mg/day) |
|---|---------|---|
| | | 200 (N=92)(N=171) |
| Psychiatric Disorders | | |
| Somnolence | 9 | 15 |
| Anorexia | 7 | 9 |
| Nervousness | 2 | 9 |
| Difficulty with Concentration/Attention | 0 | 5 |
| Insomnia | 3 | 4 |
| Difficulty with Memory | 1 | 2 |
| Aggressive Reaction | 0 | 2 |
| Respiratory System Disorders | | |
| Rhinitis | 0 | 4 |
| Urinary System Disorders | | |
| Cystitis | 0 | 2 |
| Vision Disorders | | |
| Diplopia | 0 | 2 |
| Vision Abnormal | 0 | 2 |

^a Patients in these add-on/adjunctive trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to TOPAMAX[®] or placebo.

^b Values represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.

^c Adverse reactions reported by at least 2% of patients in the TOPAMAX[®] 200 mg/day group and more common than in the placebo group are listed in this table.

Table 6: Incidence (%) of Dose-Related Adverse Reactions From Placebo-Controlled, Add-On Trials in Adults with Partial Onset Seizures^a

| Adverse Reaction | Placebo (N=216) | TOPAMAX [®] Dosage (mg/day) | | |
|--|--------------------|---|---------------|----------------------|
| | | 200 (N=45) | 400 (N=68) | 600-1,000 (N=414) |
| Fatigue | 13 | 11 | 12 | 30 |
| Nervousness | 7 | 13 | 18 | 19 |
| Difficulty with Concentration/ Attention | 1 | 7 | 9 | 14 |
| Confusion | 4 | 9 | 10 | 14 |
| Depression | 6 | 9 | 7 | 13 |
| Anorexia | 4 | 4 | 6 | 12 |
| Language problems | <1 | 2 | 9 | 10 |
| Anxiety | 6 | 2 | 3 | 10 |
| Mood problems | 2 | 0 | 6 | 9 |
| Weight decrease | 3 | 4 | 9 | 13 |

^a Dose-response studies were not conducted for other adult indications or for pediatric indications.

Table 7: Incidence (%) of Treatment-Emergent Adverse Reaction in Placebo-Controlled, Add-On Epilepsy Trials in Pediatric Patients (Ages 2 -16 Years)^{a,b} (Reaction that Occurred in at Least 1% of Topiramate-Treated Patients and Occurred More Frequently in Topiramate-Treated Than Placebo-Treated Patients)

| Body System/ Adverse Reaction | Placebo (N=101) | Topiramate (N=98) |
|--|--------------------|----------------------|
| Body as a Whole—General Disorders | | |
| Fatigue | 5 | 16 |
| Injury | 13 | 14 |
| Allergic Reaction | 1 | 2 |
| Back Pain | 0 | 1 |
| Pallor | 0 | 1 |
| Cardiovascular Disorders, General | | |
| Hypertension | 0 | 1 |
| Central & Peripheral Nervous System Disorders | | |
| Gait Abnormal | 5 | 8 |
| Ataxia | 2 | 6 |
| Hyperkinesia | 4 | 5 |
| Dizziness | 2 | 4 |
| Speech Disorders/ Related Speech Problems | 2 | 4 |
| Hyporeflexia | 0 | 2 |
| Convulsions Grand Mal | 0 | 1 |
| Fecal Incontinence | 0 | 1 |
| Paresthesia | 0 | 1 |
| Gastro-Intestinal System Disorders | | |
| Nausea | 5 | 6 |
| Saliva Increased | 4 | 6 |
| Constipation | 4 | 5 |
| Gastroenteritis | 2 | 3 |
| Dysphagia | 0 | 1 |
| Flatulence | 0 | 1 |
| Gastroesophageal Reflux | 0 | 1 |
| Glossitis | 0 | 1 |
| Gum Hyperplasia | 0 | 1 |
| Heart Rate and Rhythm Disorders | | |
| Bradycardia | 0 | 1 |
| Metabolic and Nutritional Disorders | | |
| Weight Decrease | 1 | 9 |
| Thirst | 1 | 2 |
| Hypoglycemia | 0 | 1 |
| Weight Increase | 0 | 1 |
| Platelet, Bleeding, & Clotting Disorders | | |
| Purpura | 4 | 8 |
| Epistaxis | 1 | 4 |
| Hematoma | 0 | 1 |
| Prothrombin Increased | 0 | 1 |
| Thrombocytopenia | 0 | 1 |
| Psychiatric Disorders | | |
| Somnolence | 16 | 26 |
| Anorexia | 15 | 24 |
| Nervousness | 7 | 14 |
| Personality Disorder (Behavior Problems) | 9 | 11 |
| Difficulty with Concentration/Attention | 2 | 10 |
| Aggressive Reaction | 4 | 9 |
| Insomnia | 7 | 8 |
| Difficulty with Memory NOS | 0 | 5 |
| Confusion | 3 | 4 |
| Psychomotor Slowing | 2 | 3 |
| Appetite Increased | 0 | 1 |
| Neurosis | 0 | 1 |

Table 7: Incidence (%) of Treatment-Emergent Adverse Reaction in Placebo-Controlled, Add-On Epilepsy Trials in Pediatric Patients (Ages 2 -16 Years)^{a,b} (Reaction that Occurred in at Least 1% of Topiramate-Treated Patients and Occurred More Frequently in Topiramate-Treated Than Placebo-Treated Patients) (continued)

| Body System/ Adverse Reaction | Placebo (N=101) | Topiramate (N=98) |
|---------------------------------------|--------------------|----------------------|
| Reproductive Disorders, Female | | |
| Leukorrhoea | 0 | 2 |
| Resistance Mechanism Disorders | | |
| Infection Viral | 3 | 7 |
| Respiratory System Disorders | | |
| Pneumonia | 1 | 5 |
| Respiratory Disorder | 0 | 1 |
| Skin and Appendages Disorders | | |
| Skin Disorder | 2 | 3 |
| Alopecia | 1 | 2 |
| Dermatitis | 0 | 2 |
| Hypertrichosis | 1 | 2 |
| Rash Erythematous | 0 | 2 |
| Eczema | 0 | 1 |
| Seborrhoea | 0 | 1 |
| Skin Discoloration | 0 | 1 |
| Urinary System Disorders | | |
| Urinary Incontinence | 2 | 4 |
| Nocturia | 0 | 1 |
| Vision Disorders | | |
| Eye Abnormality | 1 | 2 |
| Vision Abnormal | 1 | 2 |
| Diplopia | 0 | 1 |
| Lacrimation Abnormal | 0 | 1 |
| Myopia | 0 | 1 |
| White Cell and RES Disorders | | |
| Leukopenia | 0 | 2 |

^a Patients in these add-on/adjunctive trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to TOPAMAX® or placebo.

^b Values represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.

6.6 Other Adverse Reactions Observed During All Epilepsy Clinical Trials

Topiramate has been administered to 2,246 adults and 427 pediatric patients with epilepsy during all clinical studies, only some of which were placebo-controlled. During these studies, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reaction, similar types of reactions were grouped into a smaller number of standardized categories using modified WHOART dictionary terminology. The frequencies presented represent the proportion of patients who experienced a reaction of the type cited on at least one occasion while receiving topiramate. Reported reactions are included except those already listed in the previous tables or text, those too general to be informative, and those not reasonably associated with the use of the drug.

Reactions are classified within body system categories and enumerated in order of decreasing frequency using the following definitions: *frequent* occurring in at least 1/100 patients; *infrequent* occurring in 1/100 to 1/1000 patients; *rare* occurring in fewer than 1/1000 patients.

Autonomic Nervous System Disorders: *Infrequent*: vasodilation.

Body as a Whole: *Frequent*: syncope. *Infrequent*: abdomen enlarged. *Rare*: alcohol intolerance.

Cardiovascular Disorders, General: *Infrequent*: hypotension, postural hypotension, angina pectoris.

Central & Peripheral Nervous System Disorders: *Infrequent*: neuropathy, apraxia, hyperaesthesia, dyskinesia, dysphonia, scotoma, ptosis, dystonia, visual field defect, encephalopathy, EEG abnormal. *Rare*: upper motor neuron lesion, cerebellar syndrome, tongue paralysis.

Gastrointestinal System Disorders: *Infrequent*: hemorrhoids, stomatitis, melena, gastritis, esophagitis. *Rare*: tongue edema.

Heart Rate and Rhythm Disorders: *Infrequent*: AV block.

Liver and Biliary System Disorders: *Infrequent*: SGPT increased, SGOT increased.

Metabolic and Nutritional Disorders: *Infrequent*: dehydration, hypocalcemia, hyperlipemia, hyperglycemia, xerophthalmia, diabetes mellitus. *Rare*: hypernatremia, hyponatremia, hypocholesterolemia, creatinine increased.

Musculoskeletal System Disorders: *Frequent*: arthralgia. *Infrequent*: arthrosis.

Neoplasms: *Infrequent*: thrombocythemia. *Rare*: polycythemia.

Platelet, Bleeding, and Clotting Disorders: *Infrequent*: gingival bleeding, pulmonary embolism.

Psychiatric Disorders: *Frequent*: impotence, hallucination, psychosis, suicide attempt. *Infrequent*: euphoria, paranoid reaction, delusion, paranoia, delirium, abnormal dreaming. *Rare*: libido increased, manic reaction.

Red Blood Cell Disorders: *Frequent*: anemia. *Rare*: marrow depression, pancytopenia.

Reproductive Disorders, Male: *Infrequent*: ejaculation disorder, breast discharge.

Skin and Appendages Disorders: *Infrequent*: urticaria, photosensitivity reaction, abnormal hair texture. *Rare*: chloasma.

Special Senses Other, Disorders: *Infrequent*: taste loss, parosmia.

Urinary System Disorders: *Infrequent*: urinary retention, face edema, renal pain, albuminuria, polyuria, oliguria.

Vascular (Extracardiac) Disorders: *Infrequent*: flushing, deep vein thrombosis, phlebitis. *Rare*: vasospasm.

Vision Disorders: *Frequent*: conjunctivitis. *Infrequent*: abnormal accommodation, photophobia, strabismus. *Rare*: mydriasis, iritis.

White Cell and Reticuloendothelial System Disorders: *Infrequent*: lymphadenopathy, eosinophilia, lymphopenia, granulocytopenia. *Rare*: lymphocytosis.

6.7 Migraine

In the four multicenter, randomized, double-blind, placebo-controlled, parallel group migraine prophylaxis clinical trials, most of the adverse reactions with topiramate were mild or moderate in severity. Most adverse reactions occurred more frequently during the titration period than during the maintenance period.

Table 8 includes those adverse reactions reported for patients in the placebo-controlled trials where the incidence in any topiramate treatment group was at least 2 % and was greater than that for placebo patients.

Table 8: Incidence of Treatment-Emergent Adverse Reaction in Placebo-Controlled, Migraine Trials Where Incidence Was $\geq 2\%$ in Any Topiramate Group and Greater than the Rate in Placebo-Treated Patients^a

| Body System/ Adverse Reaction | Placebo (N=445) | TOPAMAX® Dosage (mg/day) | | |
|--|--------------------|-----------------------------|----------------|----------------|
| | | 50 (N=235) | 100 (N=386) | 200 (N=514) |
| Body as a Whole— General Disorders | | | | |
| Fatigue | 11 | 14 | 15 | 19 |
| Injury | 7 | 9 | 6 | 6 |
| Asthenia | 1 | <1 | 2 | 2 |
| Fever | 1 | 1 | 1 | 2 |
| Influenza-Like Symptoms | <1 | <1 | <1 | 2 |
| Allergy | <1 | 2 | <1 | <1 |
| Central & Peripheral Nervous System Disorders | | | | |
| Paresthesia | 6 | 35 | 51 | 49 |
| Dizziness | 10 | 8 | 9 | 12 |
| Hypoaesthesia | 2 | 6 | 7 | 8 |
| Language Problems | 2 | 7 | 6 | 7 |
| Involuntary Muscle Contractions | 1 | 2 | 2 | 4 |
| Ataxia | <1 | 1 | 2 | 1 |
| Speech Disorders/ Related Speech Problems | <1 | 1 | <1 | 2 |
| Gastro-Intestinal System Disorders | | | | |
| Nausea | 8 | 9 | 13 | 14 |
| Diarrhea | 4 | 9 | 11 | 11 |
| Abdominal Pain | 5 | 6 | 6 | 7 |
| Dyspepsia | 3 | 4 | 5 | 3 |
| Dry Mouth | 2 | 2 | 3 | 5 |
| Vomiting | 2 | 1 | 2 | 3 |
| Gastroenteritis | 1 | 3 | 3 | 2 |
| Hearing and Vestibular Disorders | | | | |
| Tinnitus | 1 | <1 | 1 | 2 |
| Metabolic and Nutritional Disorders | | | | |
| Weight Decrease | 1 | 6 | 9 | 11 |
| Thirst | <1 | 2 | 2 | 1 |
| Musculoskeletal System Disorders | | | | |
| Arthralgia | 2 | 7 | 3 | 1 |
| Neoplasms | | | | |
| Neoplasm NOS | <1 | 2 | <1 | <1 |
| Psychiatric Disorders | | | | |
| Anorexia | 6 | 9 | 15 | 14 |
| Somnolence | 5 | 8 | 7 | 10 |
| Difficulty with Memory NOS | 2 | 7 | 7 | 11 |
| Difficulty with Concentration/Attention | 2 | 3 | 6 | 10 |
| Insomnia | 5 | 6 | 7 | 6 |

Table 8: Incidence of Treatment-Emergent Adverse Reaction in Placebo-Controlled, Migraine Trials Where Incidence Was $\geq 2\%$ in Any Topiramate Group and Greater than the Rate in Placebo-Treated Patients^a (continued)

| Body System/ Adverse Reaction | Placebo (N=445) | TOPAMAX® Dosage (mg/day) | | |
|---------------------------------------|--------------------|-----------------------------|----------------|----------------|
| | | 50 (N=235) | 100 (N=386) | 200 (N=514) |
| Psychiatric Disorders | | | | |
| Anxiety | 3 | 4 | 5 | 6 |
| Mood Problems | 2 | 3 | 6 | 5 |
| Depression | 4 | 3 | 4 | 6 |
| Nervousness | 2 | 4 | 4 | 4 |
| Confusion | 2 | 2 | 3 | 4 |
| Psychomotor Slowing | 1 | 3 | 2 | 4 |
| Libido Decreased | 1 | 1 | 1 | 2 |
| Aggravated Depression | 1 | 1 | 2 | 2 |
| Agitation | 1 | 2 | 2 | 1 |
| Cognitive Problems NOS | 1 | <1 | 2 | 2 |
| Reproductive Disorders, Female | | | | |
| Menstrual Disorder | 2 | 3 | 2 | 2 |
| Reproductive Disorders, Male | | | | |
| Ejaculation Premature | 0 | 3 | 0 | 0 |
| Resistance Mechanism Disorders | | | | |
| Viral Infection | 3 | 4 | 4 | 3 |
| Otitis Media | <1 | 2 | 1 | 1 |
| Respiratory System Disorders | | | | |
| Upper Respiratory Tract Infection | 12 | 13 | 14 | 12 |
| Sinusitis | 6 | 10 | 6 | 8 |
| Pharyngitis | 4 | 5 | 6 | 2 |
| Coughing | 2 | 2 | 4 | 3 |
| Bronchitis | 2 | 3 | 3 | 3 |
| Dyspnea | 2 | 1 | 3 | 2 |
| Rhinitis | 1 | 1 | 2 | 2 |
| Skin and Appendages Disorders | | | | |
| Pruritis | 2 | 4 | 2 | 2 |
| Special Sense Other, Disorders | | | | |
| Taste Perversion | 1 | 15 | 8 | 12 |
| Taste Loss | <1 | 1 | 1 | 2 |
| Urinary System Disorders | | | | |
| Urinary Tract Infection | 2 | 4 | 2 | 4 |
| Renal Calculus | 0 | 0 | 1 | 2 |
| Vision Disorders | | | | |
| Vision Abnormal | <1 | 1 | 2 | 3 |
| Blurred Vision ^b | 2 | 4 | 2 | 4 |
| Conjunctivitis | 1 | 1 | 2 | 1 |

^a Values represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.

^b Blurred vision was the most common term considered as vision abnormal. Blurred vision was an included term that accounted for > 50 % of reactions coded as vision abnormal, a preferred term.

Of the 1,135 patients exposed to topiramate in the placebo-controlled studies, 25% discontinued due to adverse reactions, compared to 10% of the 445 placebo patients. The adverse reaction associated with discontinuing therapy in the topiramate-treated patients included paresthesia (7%), fatigue (4%), nausea (4%), difficulty with concentration/attention (3%), insomnia (3%), anorexia (2%), and dizziness (2%).

Patients treated with topiramate experienced mean percent reductions in body weight that were dose-dependent. This change was not seen in the placebo group. Mean changes of 0%, -2%, -3%, and -4% were seen for the placebo group, topiramate 50, 100, and 200 mg groups, respectively.

Table 9 shows adverse reactions that were dose-dependent. Several central nervous system adverse reactions, including some that represented cognitive dysfunction, were dose-related. The most common dose-related adverse reactions were paresthesia, fatigue, nausea, anorexia, dizziness, difficulty with memory, diarrhea, weight decrease, difficulty with concentration/attention, and somnolence.

Table 9: Incidence (%) of Dose-Related Adverse Reactions From Placebo-Controlled, Migraine Trials^a

| Adverse Reaction | Placebo (N=445) | TOPAMAX® Dosage (mg/day) | | |
|---|--------------------|-----------------------------|----------------|----------------|
| | | 50 (N=235) | 100 (N=386) | 200 (N=514) |
| Paresthesia | 6 | 35 | 51 | 49 |
| Fatigue | 11 | 14 | 15 | 19 |
| Nausea | 8 | 9 | 13 | 14 |
| Anorexia | 6 | 9 | 15 | 14 |
| Dizziness | 10 | 8 | 9 | 12 |
| Weight decrease | 1 | 6 | 9 | 11 |
| Difficulty with Memory NOS | 2 | 7 | 7 | 11 |
| Diarrhea | 4 | 9 | 11 | 11 |
| Difficulty with Concentration/Attention | 2 | 3 | 6 | 10 |
| Somnolence | 5 | 8 | 7 | 10 |
| Hypoaesthesia | 2 | 6 | 7 | 8 |
| Anxiety | 3 | 4 | 5 | 6 |
| Depression | 4 | 3 | 4 | 6 |
| Mood Problems | 2 | 3 | 6 | 5 |
| Dry Mouth | 2 | 2 | 3 | 5 |
| Confusion | 2 | 2 | 3 | 4 |
| Involuntary Muscle Contractions | 1 | 2 | 2 | 4 |
| Abnormal Vision | <1 | 1 | 2 | 3 |
| Renal Calculus | 0 | 0 | 1 | 2 |

^a The incidence of the adverse reaction in the 200 mg/day group was $\geq 2\%$ than the incidence in both the placebo group and the 50 mg/day group.

6.8 Other Adverse Reactions Observed During Migraine Clinical Trials

Topiramate, for the treatment of prophylaxis of migraine headache, has been administered to 1,367 patients in all clinical studies (includes double-blind and open-label extension). During these studies, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of reactions were grouped into a smaller number of standardized categories using modified WHOART dictionary terminology.

The following additional adverse reactions that were not described earlier were reported by greater than 1% of the 1,367 topiramate-treated patients in the controlled clinical trials:

Body as a Whole: Pain, chest pain, allergic reaction.

Central & Peripheral Nervous System Disorders: Headache, vertigo, tremor, sensory disturbance, migraine aggravated.

Gastrointestinal System Disorders: Constipation, gastroesophageal reflux.

Musculoskeletal System Disorders: Myalgia.

Platelet, Bleeding, and Clotting Disorders: Epistaxis.

Reproductive Disorders, Female: Intermenstrual bleeding.

Resistance Mechanism Disorders: Infection, genital moniliasis.

Respiratory System Disorders: Pneumonia, asthma.

Skin and Appendages Disorders: Rash, alopecia.

Vision Disorders: Abnormal accommodation, eye pain.

6.9 Postmarketing and Other Experience

In addition to the adverse experiences reported during clinical testing of TOPAMAX®, the following adverse experiences have been reported worldwide in patients receiving TOPAMAX® post-approval.

These adverse experiences have not been listed above and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: bullous skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), hepatic failure (including fatalities), hepatitis, maculopathy, pancreatitis, and pemphigus.

7 DRUG INTERACTIONS

In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5 isozymes. *In vitro* studies indicate that topiramate is a mild inhibitor of CYP2C19 and a mild inducer of CYP3A4. Drug interactions with some antiepileptic drugs, CNS depressants and oral contraceptives are described here. For other drug interactions, please refer to *Clinical Pharmacology (12.5)*.

7.1 Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. Concomitant administration of phenytoin or carbamazepine with topiramate decreased plasma concentrations of topiramate by 48% and 40% respectively when compared to TOPAMAX® given alone [see *Clinical Pharmacology (12.5)*].

In addition, concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy [see *Warnings and Precautions (5.8)* or *Clinical Pharmacology (12.5)*].

7.2 CNS Depressants

Concomitant administration of TOPAMAX® and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse events, topiramate should be used with extreme caution if used in combination with alcohol and other CNS depressants.

7.3 Oral Contraceptives

Exposure to ethinyl estradiol was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when TOPAMAX® was given as adjunctive therapy in

patients taking valproic acid). However, norethindrone exposure was not significantly affected. In another pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), TOPAMAX®, given in the absence of other medications at doses of 50 to 200 mg/day, was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX®. Patients taking estrogen-containing contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see *Clinical Pharmacology (12.5)*].

7.4 Metformin

Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see *Clinical Pharmacology (12.5)*].

7.5 Lithium

In patients, lithium levels were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (27% for C_{max} and 26% for AUC) following topiramate doses of up to 600 mg/day. Lithium levels should be monitored when co-administered with high-dose topiramate [see *Clinical Pharmacology (12.5)*].

7.6 Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide, acetazolamide or dichlorphenamide), may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation. Therefore, if topiramate is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of metabolic acidosis [see *Clinical Pharmacology (12.5)*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C.

Topiramate may cause serious adverse fetal effects, based on pregnancy registry and nonclinical data. There are no adequate and well-controlled studies using TOPAMAX® in pregnant women. TOPAMAX® should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.

Pregnancy registry data suggest that there may be an association between the use of TOPAMAX® during pregnancy and congenital malformations (e.g., craniofacial defects, such as cleft lip/palate, hypospadias, and anomalies involving various body systems). This has been reported with topiramate monotherapy and topiramate as part of a polytherapy regimen.

In addition, data from these registries and other studies suggest that, compared with monotherapy, there may be an increased risk of teratogenic effects associated with the use of anti-epileptic drugs in combination therapy.

In treating and counseling women of childbearing potential, the prescribing physician should weigh the benefits of therapy against the risks. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Pregnancy Registry

The North American Drug Pregnancy Registry has been established to collect information and provide scientific knowledge about safety and outcomes associated with pregnant women being treated with antiepileptic drugs. It is desirable that the experience from patients who are exposed to topiramate during pregnancy be reported to this registry. Such information can be reported to the North American Drug Pregnancy Registry by either a healthcare provider or the patient by calling 1-888-233-2334. Information about the North American Drug Pregnancy Registry can be found at <http://www.massgeneral.org/aed/>.

Topiramate treatment is associated with metabolic acidosis [see *Warnings and Precautions (5.4)*]. The effect of topiramate-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) may be associated with decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetus' ability to tolerate labor. Pregnant patients should be monitored for metabolic acidosis and treated as in the nonpregnant state [see *Warnings and Precautions (5.4)*]. Newborns of mothers treated with topiramate should be monitored for metabolic acidosis because of transfer of topiramate to the fetus and possible occurrence of transient metabolic acidosis following birth.

Topiramate has demonstrated selective developmental toxicity, including teratogenicity, in multiple animal species at clinically relevant doses. When oral doses of 20, 100 or 500 mg/kg were administered to pregnant mice during the period of organogenesis, the incidence of fetal malformations (primarily craniofacial defects) was increased at all doses. The low dose is approximately 0.2 times the recommended human dose (RHD) 400 mg/day on a mg/m² basis. Fetal body weights and skeletal ossification were reduced at 500 mg/kg in conjunction with decreased maternal body weight gain.

In rat studies (oral doses of 20, 100, and 500 mg/kg or 0.2, 2.5, 30, and 400 mg/kg), the frequency of limb malformations (ectrodactyly, micromelia, and amelia) was increased among the offspring of dams treated with 400 mg/kg (10 times the RHD on a mg/m² basis) or greater during the organogenesis period of pregnancy. Embryotoxicity (reduced fetal body weights, increased incidence of structural variations) was observed at doses as low as 20 mg/kg (0.5 times the RHD on a mg/m² basis). Clinical signs of maternal toxicity were seen at 400 mg/kg and above, and maternal body weight gain was reduced during treatment with 100 mg/kg or greater.

In rabbit studies (20, 60, and 180 mg/kg or 10, 35, and 120 mg/kg orally during organogenesis), embryo/fetal mortality was increased at 35 mg/kg (2 times the RHD on a mg/m² basis) or greater, and teratogenic effects (primarily rib and vertebral malformations) were observed at 120 mg/kg (6 times the RHD on a mg/m² basis). Evidence of maternal toxicity (decreased body weight gain, clinical signs, and/or mortality) was seen at 35 mg/kg and above.

When female rats were treated during the latter part of gestation and throughout lactation (0.2, 4, 20, and 100 mg/kg or 2, 20, and 200 mg/kg), offspring exhibited decreased viability and delayed physical development at 200 mg/kg (5 times the RHD on a mg/m² basis) and reductions in pre- and/or postweaning body weight gain at 2 mg/kg (0.05 times the RHD on a mg/m² basis) and above. Maternal toxicity (decreased body weight gain, clinical signs) was evident at 100 mg/kg or greater.

In a rat embryo/fetal development study with a postnatal component (0.2, 2.5, 30 or 400 mg/kg during organogenesis; noted above), pups exhibited delayed physical development at 400 mg/kg (10 times the RHD on a mg/m² basis) and persistent reductions in body weight gain at 30 mg/kg (1 times the RHD on a mg/m² basis) and higher.

8.2 Labor and Delivery

Although the effect of TOPAMAX® on labor and delivery in humans has not been established, the development of topiramate-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus' ability to tolerate labor [see *Pregnancy (8.1)*].

8.3 Nursing Mothers

Limited data on 5 breastfeeding infants exposed to topiramate showed infant plasma topiramate levels equal to 10-20% of the maternal plasma level. The effects of this exposure on infants are unknown. Caution should be exercised when administered to a nursing woman.

8.4 Pediatric Use

Adjunctive Treatment for Partial Onset Epilepsy in Infants and Toddlers (1 to 24 months)

Safety and effectiveness in patients below the age of 2 years have not been established for the adjunctive therapy treatment of partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. In a single randomized, double-blind placebo-controlled investigational trial, the efficacy, safety, and tolerability of topiramate oral liquid and sprinkle formulations as an adjunct to concurrent antiepileptic drug therapy in infants 1 to 24 months of age with refractory partial onset seizures, was assessed. After 20 days of double-blind treatment, topiramate (at fixed doses of 5, 15, and 25 mg/kg per day) did not demonstrate efficacy compared with placebo in controlling seizures.

In general, the adverse reaction profile in this population was similar to that of older pediatric patients, although results from the above controlled study, and an open-label long-term extension study in these infants/toddlers (1 to 24 months old) suggested some adverse reactions/toxicities (not previously observed in older pediatric patients and adults; i.e., growth/length retardation, certain clinical laboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications.

These very young pediatric patients appeared to experience an increased risk for infections (any topiramate dose 12%, placebo 0%) and of respiratory disorders (any topiramate dose 40%, placebo 16%). The following adverse reactions were observed in at least 3% of patients on topiramate and were 3% to 7% more frequent than in patients on placebo: viral infection, bronchitis, pharyngitis, rhinitis, otitis media, upper respiratory infection, cough, and bronchospasm. A generally similar profile was observed in older children [see *Adverse Reactions (6)*].

Topiramate resulted in an increased incidence of patients with increased creatinine (any topiramate dose 5%, placebo 0%), BUN (any topiramate dose 3%, placebo 0%), and protein (any topiramate dose 34%, placebo 6%), and an increased incidence of decreased potassium (any topiramate dose 7%, placebo 0%). This increased frequency of abnormal values was not dose-related. Creatinine was the only analyte showing a noteworthy increased incidence (topiramate 25 mg/kg/d 5%, placebo 0%) of a markedly abnormal increase [see *Warnings and Precautions (5.13)*]. The significance of these finding is uncertain.

Topiramate treatment also produced a dose-related increase in the percentage of patients who had a shift from normal at baseline to high/increased (above the normal reference range) in total eosinophil count at the end of treatment. The incidence of these abnormal shifts was 6% for placebo, 10% for 5 mg/kg/d, 9% for 15 mg/kg/d, 14% for 25 mg/kg/d, and 11% for any topiramate dose [see *Warnings and Precautions (5.13)*]. There was a mean dose-related increase in alkaline phosphatase. The significance of these finding is uncertain.

Topiramate produced a dose-related increased incidence of treatment-emergent hyperammonemia [see *Warnings and Precautions* (5.8)].

Treatment with topiramate for up to 1 year was associated with reductions in Z SCORES for length, weight, and head circumference [see *Warnings and Precautions* (5.4) and *Adverse Reactions* (6)].

In open-label, uncontrolled experience, increasing impairment of adaptive behavior was documented in behavioral testing over time in this population. There was a suggestion that this effect was dose-related. However, because of the absence of an appropriate control group, it is not known if this decrement in function was treatment related or reflects the patient's underlying disease (e.g., patients who received higher doses may have more severe underlying disease) [see *Warnings and Precautions* (5.5)].

In this open-label, uncontrolled study, the mortality was 37 deaths/1000 patient years. It is not possible to know whether this mortality rate is related to topiramate treatment, because the background mortality rate for a similar, significantly refractory, young pediatric population (1-24 months) with partial epilepsy is not known.

Monotherapy Treatment in Partial Onset Epilepsy in Patients <10 Years Old

Safety and effectiveness in patients below the age of 10 years have not been established for the monotherapy treatment of epilepsy.

Migraine Prophylaxis in Pediatrics

Safety and effectiveness in pediatric patients have not been established for the prophylaxis treatment of migraine headache.

Topiramate treatment produced a dose-related increased shift in serum creatinine from normal at baseline to an increased value at the end of 4 months treatment in adolescent patients (ages 12-16 years) who were treated for migraine prophylaxis in a double-blind, placebo-controlled study. The incidence of these abnormal shifts was 4 % for placebo, 4 % for 50 mg, and 18 % for 100 mg [see *Warnings and Precautions* (5.13)].

Juvenile Animal Studies

When topiramate (30, 90 or 300 mg/kg/day) was administered orally to rats during the juvenile period of development (postnatal days 12 to 50), bone growth plate thickness was reduced in males at the highest dose, which is approximately 5-8 times the maximum recommended pediatric dose (9 mg/kg/day) on a body surface area (mg/m²) basis.

8.5 Geriatric Use

In clinical trials, 3% of patients were over 60. No age related difference in effectiveness or adverse effects were evident. However, clinical studies of topiramate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Dosage adjustment may be necessary for elderly with impaired renal function (creatinine clearance rate <70 mL/min/1.73 m²) due to reduced clearance of topiramate [see *Clinical Pharmacology* (12.3) and *Dosage and Administration* (2.5)].

8.6 Race and Gender Effects

Evaluation of effectiveness and safety in clinical trials has shown no race or gender related effects.

8.7 Renal Impairment

The clearance of topiramate was reduced by 42% in moderately renally impaired (creatinine clearance 30 to 69 mL/min/1.73m²) and

by 54% in severely renally impaired subjects (creatinine clearance <30 mL/min/1.73m²) compared to normal renal function subjects (creatinine clearance >70 mL/min/1.73m²). One-half the usual starting and maintenance dose is recommended in patients with moderate or severe renal impairment [see *Dosage and Administration* (2.6) and *Clinical Pharmacology* (12.4)].

8.8 Patients Undergoing Hemodialysis

Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to fall below that required to maintain an anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account the duration of dialysis period, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed [see *Dosage and Administration* (2.4) and *Clinical Pharmacology* (12.4)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

TOPAMAX® (topiramate) is not a controlled substance.

9.2 Abuse

The abuse and dependence potential of TOPAMAX® has not been evaluated in human studies.

9.3 Dependence

TOPAMAX® has not been systematically studied in animals or humans for its potential for tolerance or physical dependence.

10 OVERDOSAGE

Overdoses of TOPAMAX® have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, blurred vision, diplopia, mentation impaired, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after poly-drug overdoses involving TOPAMAX®.

Topiramate overdose has resulted in severe metabolic acidosis [see *Warnings and Precautions* (5.4)].

A patient who ingested a dose between 96 and 110 g topiramate was admitted to hospital with coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days.


In acute TOPAMAX® overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate *in vitro*. Treatment should be appropriately supportive. Hemodialysis is an effective means of removing topiramate from the body.

11 DESCRIPTION

Topiramate is a sulfamate-substituted monosaccharide. TOPAMAX® (topiramate) Tablets are available as 25 mg, 50 mg, 100 mg, and 200 mg round tablets for oral administration. TOPAMAX® (topiramate capsules) Sprinkle Capsules are available as 15 mg and 25 mg sprinkle capsules for oral administration as whole capsules or opened and sprinkled onto soft food.

Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH

of 6.3. Topiramate has the molecular formula $C_{12}H_{21}NO_8S$ and a molecular weight of 339.36. Topiramate is designated chemically as 2,3:4,5-Di-*O*-isopropylidene- β -D-fructopyranose sulfamate and has the following structural formula:



TOPAMAX® (topiramate) Tablets contain the following inactive ingredients: lactose monohydrate, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hypromellose, titanium dioxide, polyethylene glycol, synthetic iron oxide (25, 50, 100, and 200 mg tablets) and polysorbate 80.

TOPAMAX® (topiramate capsules) Sprinkle Capsules contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, sorbitan monolaurate, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The precise mechanisms by which topiramate exerts its anticonvulsant and migraine prophylaxis effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and migraine prophylaxis. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.

12.2 Pharmacodynamics

Topiramate has anticonvulsant activity in rat and mouse maximal electroshock seizure (MES) tests. Topiramate is only weakly effective in blocking clonic seizures induced by the GABAA receptor antagonist, pentylenetetrazole. Topiramate is also effective in rodent models of epilepsy, which include tonic and absence-like seizures in the spontaneous epileptic rat (SER) and tonic and clonic seizures induced in rats by kindling of the amygdala or by global ischemia.

12.3 Pharmacokinetics

The sprinkle formulation is bioequivalent to the immediate release tablet formulation and, therefore, may be substituted as a therapeutic equivalent.

Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose. The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution. The bioavailability of topiramate is not affected by food.

The pharmacokinetics of topiramate are linear with dose proportional increases in plasma concentration over the dose range studied (200 to 800 mg/day). The mean plasma elimination half-life is 21 hours after single or multiple doses. Steady state is thus reached in about 4 days in patients with normal renal function. Topiramate is 15% to 41% bound to human plasma proteins over the blood concentration range of 0.5 to 250 μ g/mL. The fraction bound decreased as blood concentration increased.

Carbamazepine and phenytoin do not alter the binding of topiramate. Sodium valproate, at 500 μ g/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%. Topiramate does not influence the binding of sodium valproate.

Metabolism and Excretion

Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose). Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose. The metabolites are formed via hydroxylation, hydrolysis, and glucuronidation. There is evidence of renal tubular reabsorption of topiramate. In rats, given probenecid to inhibit tubular reabsorption, along with topiramate, a significant increase in renal clearance of topiramate was observed. This interaction has not been evaluated in humans. Overall, oral plasma clearance (CL/F) is approximately 20 to 30 mL/min in humans following oral administration.

12.4 Special Populations

Renal Impairment

The clearance of topiramate was reduced by 42% in moderately renally impaired (creatinine clearance 30 to 69 mL/min/1.73m²) and by 54% in severely renally impaired subjects (creatinine clearance <30 mL/min/1.73m²) compared to normal renal function subjects (creatinine clearance >70 mL/min/1.73m²). Since topiramate is presumed to undergo significant tubular reabsorption, it is uncertain whether this experience can be generalized to all situations of renal impairment. It is conceivable that some forms of renal disease could differentially affect glomerular filtration rate and tubular reabsorption resulting in a clearance of topiramate not predicted by creatinine clearance. In general, however, use of one-half the usual starting and maintenance dose is recommended in patients with moderate or severe renal impairment [see *Dosage and Administration (2.4) and (2.5) and Warnings and Precautions (5.11)*].

Hemodialysis

Topiramate is cleared by hemodialysis. Using a high efficiency, counterflow, single pass-dialysate hemodialysis procedure, topiramate dialysis clearance was 120 mL/min with blood flow through the dialyzer at 400 mL/min. This high clearance (compared to 20 to 30 mL/min total oral clearance in healthy adults) will remove a clinically significant amount of topiramate from the patient over the hemodialysis treatment period. Therefore, a supplemental dose may be required [see *Dosage and Administration (2.6)*].

Hepatic Impairment

In hepatically impaired subjects, the clearance of topiramate may be decreased; the mechanism underlying the decrease is not well understood [see *Dosage and Administration (2.7)*].

Age, Gender, and Race

The pharmacokinetics of topiramate in elderly subjects (65 to 85 years of age, N=16) were evaluated in a controlled clinical study. The elderly subject population had reduced renal function (creatinine clearance [-20%]) compared to young adults. Following a single oral 100 mg dose, maximum plasma concentration for elderly and young adults was achieved at approximately 1 to 2 hours. Reflecting the primary renal elimination of topiramate, topiramate plasma and renal clearance were reduced 21% and 19%, respectively, in elderly subjects, compared to young adults. Similarly, topiramate half-life was longer (13%) in the elderly. Reduced topiramate clearance resulted in slightly higher maximum plasma concentration (23%) and AUC (25%) in elderly subjects than observed in young adults. Topiramate clearance is

decreased in the elderly only to the extent that renal function is reduced. As recommended for all patients, dosage adjustment may be indicated in the elderly patient when impaired renal function (creatinine clearance rate ≤ 70 mL/min/1.73 m²) is evident. It may be useful to monitor renal function in the elderly patient [see *Dosage and Administration (2.4)* and *Warnings and Precautions (5.11)*].

Clearance of topiramate in adults was not affected by gender or race.

Pediatric Pharmacokinetics

Pharmacokinetics of topiramate were evaluated in patients ages 4 to 17 years receiving one or two other antiepileptic drugs. Pharmacokinetic profiles were obtained after one week at doses of 1, 3, and 9 mg/kg/day. Clearance was independent of dose.

Pediatric patients have a 50% higher clearance and consequently shorter elimination half-life than adults. Consequently, the plasma concentration for the same mg/kg dose may be lower in pediatric patients compared to adults. As in adults, hepatic enzyme-inducing antiepileptic drugs decrease the steady state plasma concentrations of topiramate.

12.5 Drug-Drug Interactions

Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in the *Table 10*.

In *Table 10*, the second column (AED concentration) describes what happens to the concentration of the AED listed in the first column when topiramate is added. The third column (topiramate concentration) describes how the coadministration of a drug listed in the first column modifies the concentration of topiramate in experimental settings when TOPAMAX[®] was given alone.

Table 10: Summary of AED Interactions with TOPAMAX[®]

| AED Co-administered | AED Concentration | Topiramate Concentration |
|--------------------------|----------------------------------|--------------------------|
| Phenytoin | NC or 25% increase ^a | 48% decrease |
| Carbamazepine (CBZ) | NC | 40% decrease |
| CBZ epoxide ^b | NC | NE |
| Valproic acid | 11% decrease | 14% decrease |
| Phenobarbital | NC | NE |
| Primidone | NC | NE |
| Lamotrigine | NC at TPM doses up to 400 mg/day | 13% decrease |

^a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin.

^b = Is not administered but is an active metabolite of carbamazepine.

NC = Less than 10% change in plasma concentration.

AED = Antiepileptic drug.

NE = Not Evaluated.

TPM = Topiramate

In addition to the pharmacokinetic interaction described in the above table, concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy [see *Warnings and Precautions (5.8)* and *Drug Interactions (7.1)*].

CNS Depressants

Concomitant administration of TOPAMAX[®] and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions,

topiramate should be used with extreme caution if used in combination with alcohol and other CNS depressants [see *Drug Interactions (7.2)*].

Oral Contraceptives

In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), TOPAMAX[®], given in the absence of other medications at doses of 50 to 200 mg/day, was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in patients taking valproic acid. In both studies, TOPAMAX[®] (50 mg/day to 800 mg/day) did not significantly affect exposure to NET. Although there was a dose dependent decrease in EE exposure for doses between 200 to 800 mg/day, there was no significant dose dependent change in EE exposure for doses of 50 to 200 mg/day. The clinical significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX[®]. Patients taking estrogen-containing contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see *Drug Interactions (7.3)*].

Digoxin

In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant TOPAMAX[®] administration. The clinical relevance of this observation has not been established.

Hydrochlorothiazide

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of hydrochlorothiazide (HCTZ) (25 mg q24h) and topiramate (96 mg q12h) when administered alone and concomitantly. The results of this study indicate that topiramate C_{max} increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination.

Metformin

Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated.

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin (500 mg every 12 hr) and topiramate in plasma when metformin was given alone and when metformin and topiramate (100 mg every 12 hr) were given simultaneously. The results of this study indicated that the mean metformin C_{max} and AUC_{0-12h} increased by 17% and 25%, respectively, when topiramate was added. Topiramate did not affect metformin t_{max}. The clinical significance of the effect of topiramate on metformin pharmacokinetics is not known. Oral plasma clearance of topiramate appears to be reduced when administered with metformin. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear [see *Drug Interactions (7.4)*].

Pioglitazone

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15% decrease in the $AUC_{\tau,ss}$ of pioglitazone with no alteration in $C_{max,ss}$ was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in $C_{max,ss}$ and $AUC_{\tau,ss}$ respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in $C_{max,ss}$ and $AUC_{\tau,ss}$ of the active keto-metabolite. The clinical significance of these findings is not known. When TOPAMAX® is added to pioglitazone therapy or pioglitazone is added to TOPAMAX® therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.

Glyburide

A drug-drug interaction study conducted in patients with type 2 diabetes evaluated the steady-state pharmacokinetics of glyburide (5mg/day) alone and concomitantly with topiramate (150 mg/day). There was a 22% decrease in C_{max} and 25% reduction in AUC_{24} for glyburide during topiramate administration. Systemic exposure (AUC) of the active metabolites, 4-*trans*-hydroxy-glyburide (M1) and 3-*cis*-hydroxyglyburide (M2), was also reduced by 13% and 15%, reduced C_{max} by 18% and 25%, respectively. The steady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide.

Lithium

In patients, the pharmacokinetics of lithium were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (27% for C_{max} and 26% for AUC) following topiramate doses up to 600 mg/day. Lithium levels should be monitored when co-administered with high-dose topiramate [see *Drug Interactions (7.5)*].

Haloperidol

The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of topiramate (100 mg every 12 hr) in 13 healthy adults (6 males, 7 females).

Amitriptyline

There was a 12% increase in AUC and C_{max} for amitriptyline (25 mg per day) in 18 normal subjects (9 males; 9 females) receiving 200 mg/day of topiramate. Some subjects may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patient's clinical response and not on the basis of plasma levels.

Sumatriptan

Multiple dosing of topiramate (100 mg every 12 hrs) in 24 healthy volunteers (14 males, 10 females) did not affect the pharmacokinetics of single dose sumatriptan either orally (100 mg) or subcutaneously (6 mg).

Risperidone

When administered concomitantly with topiramate at escalating doses of 100, 250 and 400 mg/day, there was a reduction in risperidone (systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses of topiramate). No alterations of 9-hydroxyrisperidone levels were observed. Coadministration of topiramate 400 mg/day with risperidone resulted in a 14% increase in C_{max} and a 12% increase in AUC_{12} of topiramate. There were no clinically significant changes in the systemic exposure of risperidone plus 9-hydroxyrisperidone or of topiramate, therefore this interaction is not likely to be of clinical significance.

Propranolol

Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 males, 17 females) did not affect the pharmacokinetics of propranolol following daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27 males, 12 females) had no effect on the exposure to topiramate at a dose of 200 mg/day of topiramate.

Dihydroergotamine

Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 males, 12 females) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study.

Diltiazem

Co-administration of diltiazem (240 mg Cardizem CD®) with topiramate (150 mg/day) resulted in a 10% decrease in C_{max} and 25% decrease in diltiazem AUC, 27% decrease in C_{max} and 18% decrease in des-acetyl diltiazem AUC, and no effect on N-desmethyl diltiazem. Coadministration of topiramate with diltiazem resulted in a 16% increase in C_{max} and a 19% increase in AUC_{12} of topiramate.

Venlafaxine

Multiple dosing of topiramate (150 mg/day) in healthy volunteers did not affect the pharmacokinetics of venlafaxine or O-desmethyl venlafaxine. Multiple dosing of venlafaxine (150 mg Effexor XR®) did not affect the pharmacokinetics of topiramate.

Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide, acetazolamide or dichlorphenamide), may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation. Therefore, if topiramate is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of metabolic acidosis [see *Drug Interactions (7.6)*].

Drug/Laboratory Tests Interactions

There are no known interactions of topiramate with commonly used laboratory tests.

13 NON-CLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility *Carcinogenesis*

An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximately 0.5 to 1 times steady-state exposures measured in patients receiving topiramate monotherapy at the recommended human dose (RHD) of 400 mg, and 1.5 to 2 times steady-state topiramate exposures in patients receiving 400 mg of topiramate plus phenytoin. The relevance of this finding to human carcinogenic risk is uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg (approximately 3 times the RHD on a mg/m² basis).

Mutagenesis

Topiramate did not demonstrate genotoxic potential when tested in a battery of *in vitro* and *in vivo* assays. Topiramate was not mutagenic in the Ames test or the *in vitro* mouse lymphoma assay; it did not increase unscheduled DNA synthesis in rat hepatocytes *in vitro*; and it did not increase chromosomal aberrations in human lymphocytes *in vitro* or in rat bone marrow *in vivo*.

Impairment of Fertility

No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (2.5 times the RHD on a mg/m² basis).

14 CLINICAL STUDIES


The studies described in the following sections were conducted using TOPAMAX® (topiramate) Tablets.

14.1 Monotherapy Epilepsy Controlled Trial

The effectiveness of topiramate as initial monotherapy in adults and children 10 years of age and older with partial onset or primary generalized seizures was established in a multicenter, randomized, double-blind, parallel-group trial.

The trial was conducted in 487 patients diagnosed with epilepsy (6 to 83 years of age) who had 1 or 2 well-documented seizures during the 3-month retrospective baseline phase who then entered the study and received topiramate 25 mg/day for 7 days in an open-label fashion. Forty-nine percent of subjects had no prior AED treatment and 17% had a diagnosis of epilepsy for greater than 24 months. Any AED therapy used for temporary or emergency purposes was discontinued prior to randomization. In the double-blind phase, 470 patients were randomized to titrate up to 50 mg/day or 400 mg/day. If the target dose could not be achieved, patients were maintained on the maximum tolerated dose. Fifty eight percent of patients achieved the maximal dose of 400 mg/day for >2 weeks, and patients who did not tolerate 150 mg/day were discontinued. The primary efficacy assessment was a between group comparison of time to first seizure during the double-blind phase. Comparison of the Kaplan-Meier survival curves of time to first seizure favored the topiramate 400 mg/day group over the topiramate 50 mg/day group ($p=0.0002$, log rank test; *Figure 1*). The treatment effects with respect to time to first seizure were consistent across various patient subgroups defined by age, sex, geographic region, baseline body weight, baseline seizure type, time since diagnosis, and baseline AED use.

Figure 1: Kaplan-Meier Estimates of Cumulative Rates for Time to First Seizure



Adjunctive Therapy Controlled Trials in Patients With Partial Onset Seizures

The effectiveness of topiramate as an adjunctive treatment for adults with partial onset seizures was established in six multicenter, randomized, double-blind, placebo controlled trials, two comparing several dosages of topiramate and placebo and four comparing a single dosage with placebo, in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

Patients in these studies were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX® tablets or placebo. In each study, patients were stabilized on optimum dosages of their concomitant AEDs during baseline phase lasting between 4 and 12 weeks. Patients who experienced a prespecified minimum number of partial onset seizures, with or without secondary generalization, during the baseline phase (12 seizures for 12-week baseline, 8 for 8-week baseline or 3 for 4-week baseline) were randomly assigned to placebo or a specified dose of TOPAMAX® tablets in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. In five of the six studies, patients received active drug beginning at 100 mg per day; the dose was then increased by 100 mg or 200 mg/day increments weekly or every other week until the assigned dose was reached, unless intolerance prevented increases. In the sixth study (119), the 25 or 50 mg/day initial doses of topiramate were followed by respective weekly increments of 25 or 50 mg/day until the target dose of 200 mg/day was reached. After titration, patients entered a 4, 8 or 12-week stabilization period. The numbers of patients randomized to each dose, and the actual mean and median doses in the stabilization period are shown in *Table 11*.

Adjunctive Therapy Epilepsy Controlled Trials in Adults and Pediatric Patients (Ages 2 to 16 Years)

The effectiveness of topiramate as an adjunctive treatment for pediatric patients ages 2 to 16 years with partial onset seizures was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing topiramate and placebo in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX® tablets or placebo. In this study, patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least six partial onset seizures, with or without secondarily generalized seizures, during the baseline phase were randomly assigned to placebo or TOPAMAX® tablets in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 25 or 50 mg per day; the dose was then increased by 25 mg to 150 mg/day increments every other week until the assigned dosage of 125, 175, 225 or 400 mg/day based on patients' weight to approximate a dosage of 6 mg/kg per day was reached, unless intolerance prevented increases. After titration, patients entered an 8-week stabilization period.

Adjunctive Therapy Controlled Trial in Patients With Primary Generalized Tonic-Clonic Seizures

The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-clonic seizures in patients 2 years old and older was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing a single dosage of topiramate and placebo.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX® or placebo. Patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least three primary generalized tonic-clonic seizures during the baseline phase were randomly assigned to placebo or TOPAMAX® in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 50 mg per day for four weeks; the dose was then increased by 50 mg to 150 mg/day increments every other week until the assigned dose of 175, 225 or 400 mg/day based on patients' body weight to approximate a dosage of 6 mg/kg per day was reached, unless intolerance prevented increases. After titration, patients entered a 12-week stabilization period.

Adjunctive Therapy Controlled Trial in Patients With Lennox-Gastaut Syndrome

The effectiveness of topiramate as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome was established in a multicenter, randomized, double-blind, placebo-controlled trial comparing a single dosage of topiramate with placebo in patients 2 years of age and older.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX® or placebo. Patients who were experiencing at least 60 seizures per month before study entry were stabilized on optimum dosages of their concomitant AEDs during a 4-week baseline phase. Following baseline, patients were randomly assigned to placebo or TOPAMAX® in addition to their other AEDs. Active drug was titrated beginning at 1 mg/kg per day for a week; the dose was then increased to 3 mg/kg per day for one week then to 6 mg/kg per day. After titration, patients entered an 8-week stabilization period. The primary measures of effectiveness were the percent reduction in drop attacks and a parental global rating of seizure severity.

Table 11: Topiramate Dose Summary During the Stabilization Periods of Each of Six Double-Blind, Placebo-Controlled, Add-On Trials in Adults with Partial Onset Seizures^b

| Protocol | Stabilization Dose | Placebo ^a | Target Topiramate Dosage (mg/day) | | | | |
|----------|--------------------|----------------------|-----------------------------------|-----|-----|-----|-------|
| | | | 200 | 400 | 600 | 800 | 1,000 |
| YD | N | 42 | 42 | 40 | 41 | — | — |
| | Mean Dose | 5.9 | 200 | 390 | 556 | — | — |
| | Median Dose | 6.0 | 200 | 400 | 600 | — | — |
| YE | N | 44 | — | — | 40 | 45 | 40 |
| | Mean Dose | 9.7 | — | — | 544 | 739 | 796 |
| | Median Dose | 10.0 | — | — | 600 | 800 | 1,000 |
| Y1 | N | 23 | — | 19 | — | — | — |
| | Mean Dose | 3.8 | — | 395 | — | — | — |
| | Median Dose | 4.0 | — | 400 | — | — | — |
| Y2 | N | 30 | — | — | 28 | — | — |
| | Mean Dose | 5.7 | — | — | 522 | — | — |
| | Median Dose | 6.0 | — | — | 600 | — | — |
| Y3 | N | 28 | — | — | — | 25 | — |
| | Mean Dose | 7.9 | — | — | — | 568 | — |
| | Median Dose | 8.0 | — | — | — | 600 | — |
| 119 | N | 90 | 157 | — | — | — | — |
| | Mean Dose | 8 | 200 | — | — | — | — |
| | Median Dose | 8 | 200 | — | — | — | — |

^a Placebo dosages are given as the number of tablets. Placebo target dosages were as follows: Protocol Y1, 4 tablets/day; Protocols YD and Y2, 6 tablets/day; Protocol Y3 and 119, 8 tablets/day; Protocol YE, 10 tablets/day.

^b Dose-response studies were not conducted for other indications or pediatric partial onset seizures.

In all add-on trials, the reduction in seizure rate from baseline during the entire double-blind phase was measured. The median percent reductions in seizure rates and the responder rates (fraction of patients with at least a 50% reduction) by treatment group for each study are shown below in *Table 12*. As described above, a global improvement in seizure severity was also assessed in the Lennox-Gastaut trial.

Table 12: Efficacy Results in Double-Blind, Placebo-Controlled, Add-On Epilepsy Trials

| Protocol | Efficacy Results | Placebo | Target Topiramate Dosage (mg/day) | | | | | |
|---|--|---------|-----------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| | | | 200 | 400 | 600 | 800 | 1,000 | ≈6 mg/kg/day* |
| Partial Onset Seizures | | | | | | | | |
| Studies in Adults | | | | | | | | |
| YD | N | 45 | 45 | 45 | 46 | — | — | — |
| | Median % Reduction | 11.6 | 27.2 ^a | 47.5 ^b | 44.7 ^c | — | — | — |
| | % Responders | 18 | 24 | 44 ^d | 46 ^d | — | — | — |
| YE | N | 47 | — | — | 48 | 48 | 47 | — |
| | Median % Reduction | 1.7 | — | — | 40.8 ^c | 41.0 ^c | 36.0 ^c | — |
| | % Responders | 9 | — | — | 40 ^c | 41 ^c | 36 ^d | — |
| Y1 | N | 24 | — | 23 | — | — | — | — |
| | Median % Reduction | 1.1 | — | 40.7 ^e | — | — | — | — |
| | % Responders | 8 | — | 35 ^d | — | — | — | — |
| Y2 | N | 30 | — | — | 30 | — | — | — |
| | Median % Reduction | -12.2 | — | — | 46.4 ^f | — | — | — |
| | % Responders | 10 | — | — | 47 ^c | — | — | — |
| Y3 | N | 28 | — | — | — | 28 | — | — |
| | Median % Reduction | -20.6 | — | — | — | 24.3 ^c | — | — |
| | % Responders | 0 | — | — | — | 43 ^c | — | — |
| 119 | N | 91 | 168 | — | — | — | — | — |
| | Median % Reduction | 20.0 | 44.2 ^c | — | — | — | — | — |
| | % Responders | 24 | 45 ^c | — | — | — | — | — |
| Studies in Pediatric Patients | | | | | | | | |
| YP | N | 45 | — | — | — | — | — | 41 |
| | Median % Reduction | 10.5 | — | — | — | — | — | 33.1 ^d |
| | % Responders | 20 | — | — | — | — | — | 39 |
| Primary Generalized Tonic-Clonic ^h | | | | | | | | |
| YTC | N | 40 | — | — | — | — | — | 39 |
| | Median % Reduction | 9.0 | — | — | — | — | — | 56.7 ^d |
| | % Responders | 20 | — | — | — | — | — | 56 ^c |
| Lennox-Gastaut Syndrome ⁱ | | | | | | | | |
| YL | N | 49 | — | — | — | — | — | 46 |
| | Median % Reduction | -5.1 | — | — | — | — | — | 14.8 ^d |
| | % Responders | 14 | — | — | — | — | — | 28 ^g |
| | Improvement in Seizure Severity ^j | 28 | — | — | — | — | — | 52 ^d |

Comparisons with placebo: ^a p=0.080; ^b p≤ 0.010; ^c p≤ 0.001; ^d p≤ 0.050; ^e p=0.065; ^f p≤ 0.005; ^g p=0.071;

^h Median % reduction and % responders are reported for PGTC Seizures;

ⁱ Median % reduction and % responders for drop attacks, i.e., tonic or atonic seizures;

^j Percent of subjects who were minimally, much, or very much improved from baseline

* For Protocols YP and YTC, protocol-specified target dosages (<9.3 mg/kg/day) were assigned based on subject's weight to approximate a dosage of 6 mg/kg per day; these dosages corresponded to mg/day dosages of 125, 175, 225, and 400 mg/day.

Subset analyses of the antiepileptic efficacy of TOPAMAX® tablets in these studies showed no differences as a function of gender, race, age, baseline seizure rate, or concomitant AED.

In clinical trials for epilepsy, daily dosages were decreased in weekly intervals by 50 to 100 mg per day in adults and over a 2 to 8 week period in children; transition was permitted to a new antiepileptic regimen when clinically indicated.

14.2 Migraine Prophylaxis

The results of 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials established the effectiveness of TOPAMAX® in the prophylactic treatment of migraine headache. The design of both trials (one study was conducted in the US and one study was conducted in the US and Canada) was identical, enrolling patients with a history of migraine, with or without aura, for at least 6 months, according to the International Headache Society diagnostic criteria. Patients with a history of cluster headaches or basilar, ophthalmoplegic, hemiplegic or transformed migraine headaches were excluded from the trials. Patients were required to have completed up to a 2-week washout of any prior migraine preventive medications before starting the baseline phase.

Patients who experienced 3 to 12 migraine headaches over the 4-weeks in the baseline phase were equally randomized to either TOPAMAX® 50 mg/day, 100 mg/day, 200 mg/day or placebo and treated for a total of 26 weeks (8-week titration period and 18-week maintenance period). Treatment was initiated at 25 mg/day for one week, and then the daily dosage was increased by 25 mg increments each week until reaching the assigned target dose or maximum tolerated dose (administered twice daily).

Effectiveness of treatment was assessed by the reduction in migraine headache frequency, as measured by the change in 4-week migraine rate from the baseline phase to double-blind treatment period in each TOPAMAX® treatment group compared to placebo in the intent to treat (ITT) population.

In the first study, a total of 469 patients (416 females, 53 males), ranging in age from 13 to 70 years, were randomized and provided efficacy data. Two hundred sixty five patients completed the entire 26-week double-blind phase. The median average daily dosages were 47.8 mg/day, 88.3 mg/day, and 132.1 mg/day in the target dose groups of TOPAMAX® 50, 100, and 200 mg/day, respectively.

The mean migraine headache frequency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache frequency from baseline to the double-blind phase was -1.3, -2.1, and -2.2 in the TOPAMAX® 50, 100, and 200 mg/day groups, respectively, versus -0.8 in the placebo group (see Figure 2). The differences between the TOPAMAX® 100 and 200 mg/day groups versus placebo were statistically significant ($p < 0.001$ for both comparisons).


In the second study, a total of 468 patients (406 females, 62 males), ranging in age from 12 to 65 years, were randomized and provided efficacy data. Two hundred fifty five patients completed the entire 26-week double-blind phase. The median average daily dosages were 46.5 mg/day, 85.6 mg/day, and 150.2 mg/day in the target dose groups of TOPAMAX® 50, 100, and 200 mg/day, respectively.

The mean migraine headache frequency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache period frequency from baseline to the double-blind phase was -1.4, -2.1, and -2.4 in the TOPAMAX® 50, 100, and 200 mg/day groups, respectively, versus -1.1 in the placebo group (see Figure 2). The differences between the TOPAMAX® 100 and 200 mg/day groups versus placebo were statistically significant ($p = 0.008$ and < 0.001 , respectively).

In both studies, there were no apparent differences in treatment effect within age or gender, subgroups. Because most patients were Caucasian, there were insufficient numbers of patients from different races to make a meaningful comparison of race.

For patients withdrawing from TOPAMAX®, daily dosages were decreased in weekly intervals by 25 to 50 mg per day.

Figure 2: Reduction in 4-Week Migraine Headache Frequency (Studies TOPMAT-MIGR-001 and TOPMAT-MIGR-002)



16 HOW SUPPLIED/STORAGE AND HANDLING

TOPAMAX® Tablets

TOPAMAX® (topiramate) Tablets are available as debossed, coated, round tablets in the following strengths and colors:

25 mg cream tablet (debossed “OMN” on one side; “25” on the other) and are available in bottles of 60 count with desiccant (NDC 50458-639-65)

50 mg light yellow tablet (debossed “OMN” on one side; “50” on the other) and are available in bottles of 60 count with desiccant (NDC 50458-640-65)

100 mg yellow tablet (debossed “OMN” on one side; “100” on the other) and are available in bottles of 60 count with desiccant (NDC 50458-641-65)

200 mg salmon tablet (debossed “OMN” on one side; “200” on the other) and are available in bottles of 60 count with desiccant (NDC 50458-642-65)

TOPAMAX® Sprinkle Capsules

TOPAMAX® (topiramate capsules) Sprinkle Capsules contain small, white to off white spheres. The gelatin capsules are white and clear and are marked as follows:

15 mg capsule with “TOP” and “15 mg” on the side and are available in bottles of 60 (NDC 50458-647-65)

25 mg capsule with “TOP” and “25 mg” on the side and are available in bottles of 60 (NDC 50458-645-65)

Storage and Handling

TOPAMAX® (topiramate) Tablets should be stored in tightly-closed containers at controlled room temperature (59° to 86°F, 15° to 30°C). Protect from moisture.

TOPAMAX® (topiramate capsules) Sprinkle Capsules should be stored in tightly-closed containers at or below 25°C (77°F). Protect from moisture.

17 PATIENT COUNSELING INFORMATION

Patients and their caregivers should be informed of the availability of a Medication Guide, and they should be instructed to read the Medication Guide prior to taking TOPAMAX®. Patients should be instructed to take TOPAMAX® only as prescribed. See FDA approved Medication Guide.

17.1 Eye Disorders

Patients taking TOPAMAX® should be told to seek immediate medical attention if they experience blurred vision, visual disturbances or periorbital pain [see *Warnings and Precautions (5.1)*].

17.2 Oligohydrosis and Hyperthermia

Patients, especially pediatric patients, treated with TOPAMAX® should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather [see *Warnings and Precautions (5.2)*].

17.3 Suicidal Behavior and Ideation

Patients, their caregivers, and families should be counseled that AEDs, including Topamax, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior or the emergence of suicidal thoughts, behavior or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

17.4 Metabolic Acidosis

Patients should be warned about the potential, significant risk for metabolic acidosis that may be asymptomatic and may be associated with adverse effects on kidneys (e.g., kidney stones, nephrocalcinosis), bones (e.g., osteoporosis, osteomalacia, and/or rickets in children), and growth (e.g., growth delay/retardation) in pediatric patients [see *Warnings and Precautions (5.4)*].

17.5 Interference with Cognitive and Motor Performance

Patients should be warned about the potential for somnolence, dizziness, confusion, difficulty concentrating, visual effects and advised not to drive or operate machinery until they have gained sufficient experience on topiramate to gauge whether it adversely affects their mental performance, motor performance, and/or vision [see *Warnings and Precautions (5.5)*].

Even when taking TOPAMAX® or other anticonvulsants, some patients with epilepsy will continue to have unpredictable seizures. Therefore, all patients taking TOPAMAX® for epilepsy should be told to exercise appropriate caution when engaging in any activities where loss of consciousness could result in serious danger to themselves or those around them (including swimming, driving a car, climbing in high places, etc.). Some patients with refractory epilepsy will need to avoid such activities altogether. Physicians should discuss the appropriate level of caution with their patients, before patients with epilepsy engage in such activities.

17.6 Hyperammonemia and Encephalopathy

Patients should be warned about the possible development of hyperammonemia with or without encephalopathy. Although hyperammonemia may be asymptomatic, clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. This hyperammonemia and encephalopathy can develop with topiramate treatment alone or with topiramate treatment with concomitant valproic acid (VPA).

Patients should be instructed to contact their physician if they develop unexplained lethargy, vomiting, or changes in mental status [see *Warnings and Precautions (5.8)*].

17.7 Kidney Stones

Patients, particularly those with predisposing factors, should be instructed to maintain an adequate fluid intake in order to minimize the risk of kidney stone formation [see *Warnings and Precautions (5.9)*].

17.8 Use in Pregnancy

Patients should be instructed to notify their physician if they become pregnant or intend to become pregnant during therapy and to notify their physician if they are breastfeeding or intend to breastfeed during therapy with TOPAMAX® [see *Use in Specific Populations (8.1) and (8.3)*].

Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. The registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number, 1-888-233-2334 [see *Use in Specific Populations (8.1)*].

Manufactured by:
Janssen Ortho, LLC
Gurabo, Puerto Rico 00778

Manufactured for:
Ortho-McNeil Neurologics,
Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Titusville, NJ 08560



© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009

7517119

Revised December 2009

MEDICATION GUIDE TOPAMAX® (Toe-pa-max) (topiramate)

Tablets and Sprinkle Capsules

Read this Medication Guide before you start taking TOPAMAX® and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. If you have any questions about TOPAMAX®, talk to your healthcare provider or pharmacist.

What is the most important information I should know about TOPAMAX®?

- **TOPAMAX® may cause eye problems.** Serious eye problems include:
 - o any sudden decrease in vision with or without eye pain and redness,
 - o a blockage of fluid in the eye causing increased pressure in the eye (secondary angle closure glaucoma).
 - o These eye problems can lead to permanent loss of vision if not treated. You should call your healthcare provider right away if you have any new eye symptoms.
- **TOPAMAX® may cause decreased sweating and increased body temperature (fever).** People, especially children, should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition.
- **Like other antiepileptic drugs, TOPAMAX® may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.**

Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

- thoughts about suicide or dying
- attempts to commit suicide
- new or worse depression
- new or worse anxiety
- feeling agitated or restless
- panic attacks
- trouble sleeping (insomnia)
- new or worse irritability
- acting aggressive, being angry, or violent
- acting on dangerous impulses
- an extreme increase in activity and talking (mania)
- other unusual changes in behavior or mood

Do not stop TOPAMAX® without first talking to a healthcare provider.

- Stopping TOPAMAX® suddenly can cause serious problems.
- Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

How can I watch for early symptoms of suicidal thoughts and actions?

- Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
- Keep all follow-up visits with your healthcare provider as scheduled.
- Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

What is TOPAMAX®?

TOPAMAX® is a prescription medicine used:

- to treat certain types of seizures (partial onset seizures and primary generalized tonic-clonic seizures) in people 10 years and older,
- with other medicines to treat certain types of seizures (partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome) in adults and children 2 years and older,
- to prevent migraine headaches in adults.

What should I tell my healthcare provider before taking TOPAMAX®?

Before taking TOPAMAX®, tell your healthcare provider about all your medical conditions, including if you:

- have or have had depression, mood problems or suicidal thoughts or behavior
- have kidney problems, kidney stones or are getting kidney dialysis
- have a history of metabolic acidosis (too much acid in the blood)
- have liver problems
- have osteoporosis, soft bones, or decreased bone density
- have lung or breathing problems
- have eye problems, especially glaucoma
- have diarrhea
- have a growth problem
- are on a diet high in fat and low in carbohydrates, which is called a ketogenic diet
- are having surgery

- are pregnant or plan to become pregnant. It is not known if TOPAMAX® will harm your unborn baby. If you become pregnant while taking TOPAMAX®, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy.
- are breastfeeding. It is not known if TOPAMAX® passes into breast milk and if it can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take TOPAMAX®.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. TOPAMAX® and other medicines may affect each other causing side effects.

Especially, tell your healthcare provider if you take:

- Valproic acid (DEPAKENE®, DEPAKOTE®)
- any medicines that impair or decrease your thinking, concentration, or muscle coordination.
- birth control pills. TOPAMAX® may make your birth control pills less effective. Tell your healthcare provider if your menstrual bleeding changes while you are taking birth control pills and TOPAMAX®.

Ask your healthcare provider if you are not sure if your medicine is listed above.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine. Do not start a new medicine without talking with your healthcare provider.

How should I take TOPAMAX®?

- Take TOPAMAX® exactly as prescribed.
- Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.
- TOPAMAX® tablets should be swallowed whole. Do not chew the tablets. They may leave a bitter taste.
- TOPAMAX® sprinkle capsules may be swallowed whole or may be opened and sprinkled on a teaspoon of soft food. Drink fluids right after eating the food and medicine mixture to make sure it is all swallowed.
- Do not store any medicine and food mixture for later use.
- TOPAMAX® can be taken before, during, or after a meal. Drink plenty of fluids during the day. This may help prevent kidney stones while taking TOPAMAX®.
- If you take too much TOPAMAX®, call your healthcare provider or poison control center right away or go to the nearest emergency room.
- If you miss a single dose of TOPAMAX®, take it as soon as you can. However, if you are within 6 hours of taking your next scheduled dose, wait until then to take your usual dose of TOPAMAX®, and skip the missed dose. Do not double your dose. If you have missed more than one dose, you should call your healthcare professional for advice.
- Do not stop taking TOPAMAX® without talking to your healthcare provider. Stopping TOPAMAX® suddenly may cause serious problems. If you have epilepsy and you stop taking TOPAMAX® suddenly, you may have seizures that do not stop. Your healthcare provider will tell you how to stop taking TOPAMAX® slowly.

- Your healthcare provider may do blood tests while you take TOPAMAX®.

What should I avoid while taking TOPAMAX®?

- Do not drink alcohol while taking TOPAMAX®. TOPAMAX® and alcohol can affect each other causing side effects such as sleepiness and dizziness.
- Do not drive a car or operate heavy machinery until you know how TOPAMAX® affects you. TOPAMAX® can slow your thinking, motor skills, and/or vision.

What are the possible side effects of TOPAMAX®?

TOPAMAX® may cause serious side effects including:

See “What is the most important information I should know about TOPAMAX®?”

- **Metabolic Acidosis.** Metabolic acidosis can cause:
 - o tiredness
 - o loss of appetite
 - o irregular heartbeat
 - o impaired consciousness
- **High blood ammonia levels.** High ammonia in the blood can affect your mental activities, slow your alertness, make you feel tired, or cause vomiting. This has happened when TOPAMAX® is taken with a medicine called valproic acid (DEPAKENE® and DEPAKOTE®).
- **Kidney stones.** Drink plenty of fluids when taking TOPAMAX® to decrease your chances of getting kidney stones.
- **Effects on Thinking and Alertness.** TOPAMAX® may affect how you think, and cause confusion, problems with concentration, attention, memory, or speech. TOPAMAX® may cause depression or mood problems, tiredness, and sleepiness.
- **Dizziness or Loss of Muscle Coordination.**

Call your healthcare provider right away if you have any of the symptoms above.

The most common side effects of TOPAMAX® include:

- tingling of the arms and legs (paresthesia)
- not feeling hungry
- nausea
- a change in the way foods taste
- diarrhea
- weight loss
- nervousness
- upper respiratory tract infection

Tell your healthcare provider about any side effect that bothers you or that does not go away.

These are not all the possible side effects of TOPAMAX®. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store TOPAMAX®?

- Store TOPAMAX® tablets at room temperature, 59°F to 86°F (15°C to 30°C).
- Store TOPAMAX® Sprinkle Capsules at or below 25°C (77°F).
- Keep TOPAMAX® in a tightly closed container.
- Keep TOPAMAX® dry and away from moisture.
- **Keep TOPAMAX® and all medicines out of the reach of children.**

General information about TOPAMAX®.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TOPAMAX® for a condition for which it was not prescribed. Do not give TOPAMAX® to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about TOPAMAX®. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about TOPAMAX® that is written for health professionals.

For more information, go to www.topamax.com or call 1-800-526-7736.

What are the ingredients in TOPAMAX®?

Active ingredient: topiramate

Inactive ingredients:

- **Tablets** - lactose monohydrate, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hypromellose, titanium dioxide, polyethylene glycol, synthetic iron oxide and polysorbate 80.
- **Sprinkle Capsules** - sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, sorbitan monolaurate, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink.

Manufactured by: Janssen Ortho, LLC Gurabo, Puerto Rico 00778

Manufactured for: Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Titusville, NJ 08560



© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Revised December 2009

7517119